SELLAS Life Sciences (SLS) 10-K 22 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 21, 2019	Jun. 29, 2018
Document Document And Entity Information [Abstract]
Entity Registrant Name	SELLAS Life Sciences Group, Inc.
Trading Symbol	SLS
Entity Central Index Key	0001390478
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Public Float			$ 14,425,577
Entity Common Stock, Shares Outstanding		23,176,475

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 5,337	$ 2,319
Restricted cash and cash equivalents	114	10,431
Prepaid expenses and other current assets	387	337
Total current assets	5,838	13,087
In-process research and development	8,500	17,600
Goodwill	1,914	1,914
Deposits and other assets	663	925
Total assets	16,915	33,526
Current liabilities:
Current portion of long-term debt	0	8,377
Accounts payable	3,755	11,691
Accrued expenses and other current liabilities	2,219	3,201
Litigation settlement payable	0	1,300
Total current liabilities	5,974	24,569
Deferred tax liability	357	1,673
Warrant liability	1,013	1,309
Contingent consideration	4,326	1,294
Long-term debt, net of current portion	0	2,611
Total liabilities	11,670	31,456
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at December 31, 2018 and December 31, 2017	0	0
Common stock, $0.0001 par value; 350,000,000 shares authorized, 22,026,476 shares issued and outstanding at December 31, 2018; 5,766,891 shares issued and outstanding at December 31, 2017	2	1
Additional paid-in capital	87,098	56,254
Accumulated deficit	(81,855)	(54,185)
Total stockholders’ equity	5,245	2,070
Total liabilities and stockholders’ equity	$ 16,915	$ 33,526

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	22,026,476	5,766,891
Common stock, shares outstanding (in shares)	22,026,476	5,766,891
Series A Preferred Stock
Preferred stock, shares authorized (in shares)	17,500

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating expenses:
Research and development	$ 8,767	$ 6,067
General and administrative	12,772	15,089
In-process research and development impairment charge	9,550	0
Severance costs related to Merger	0	1,883
Total operating expenses and operating loss	(31,089)	(23,039)
Non-operating income (expense):
Change in fair value of warrant liability	5,300	0
Change in fair value of contingent consideration	(3,032)	0
Loss on settlement of liability-classified warrants	(727)	0
Gain on extinguishment of debt	766	0
Interest expense, net	(266)	(462)
Total non-operating income (expense), net	2,041	(462)
Loss before income taxes	(29,048)	(23,501)
Income tax expense (benefit)	(1,378)	253
Net loss	(27,670)	(23,754)
Deemed dividend arising from beneficial conversion feature of convertible preferred stock	(4,436)	0
Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision	(8,654)	0
Impact of anti-dilution protection on liability-classified warrants	(491)	0
Deemed dividend on conversion of 2015 Sely Note	0	(675)
Net loss attributable to common stockholders	$ (41,251)	$ (24,429)
Per share information:
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)	$ (3.15)	$ (10.44)
Weighted-average common shares outstanding, basic and diluted (in shares)	13,077,140	2,340,368

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Patel vs Galena biopharma, Inc	Patel vs Galena biopharma, IncCommon Stock	Patel vs Galena biopharma, IncAdditional Paid-In Capital	Secured Debt	Secured DebtCommon Stock	Secured DebtAdditional Paid-In Capital	Convertible Preferred Stock	Convertible Preferred StockPreferred Stock	Convertible Preferred StockCommon Stock	Convertible Preferred StockAdditional Paid-In Capital	Convertible Notes Payable	Convertible Notes PayableCommon Stock	Convertible Notes PayableAdditional Paid-In Capital
Beginning balance (in shares) at Dec. 31, 2016		0	1,268,489
Beginning balance at Dec. 31, 2016	$ (4,997,000)	$ 0	$ 0	$ 25,434,000	$ (30,431,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued in connection with amendments to MSK license, shares			83,594
Stock issued in connection with amendments to MSK license, amount	388,000			388,000
Issuance of common stock (in shares)			330,551
Issuance of common stock as result of conversion	1,294,000			1,294,000
Issuance of stock (in shares)			1,534,711
Issuance of stock, amount	6,007,000			6,007,000
Shares issued in connection with settlement of related party payables, shares			96,662
Shares issued in connection with settlement of related party payables, amount	378,000			378,000
Shares issued upon the acceleration of restricted stock units, shares			46,373
Shares issued upon cancellation of Equilibria restricted stock units, shares			58,208
Shares issued in connection with acquisition of Galena, shares			1,588,605
Shares issued in connection with acquisition of Galena	12,487,000		$ 1,000	12,486,000
Fair value of assumed options issued in connection with acquisition of Galena	32,000			32,000
Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria, shares			632,326
Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria, value	6,739,000			6,739,000
Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria	$ (675,000)			(675,000)
Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena, shares	119,672		119,672
Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena	$ 941,000			941,000
Shares issued to MSK for anti-dilution provisions, shares			7,700
Shares issued to MSK for anti-dilution provisions	61,000			61,000
Stock-based compensation expense	3,169,000			3,169,000
Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision	0
Net loss	(23,754,000)				(23,754)
Ending balance (in shares) at Dec. 31, 2017		0	5,766,891
Ending balance at Dec. 31, 2017	2,070,000	$ 0	$ 1,000	56,254,000	(54,185,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)		(2,898)	499,682										(7,802)	3,748,184			118,644
Issuance of common stock as result of conversion												$ (8,654,000)			$ (8,654,000)	$ 825,000		$ 825,000
Issuance of stock (in shares)		10,700	6,845,000				228,672			715,277
Issuance of stock, amount	21,564,000		$ 1,000	21,563,000		$ 1,250,000		$ 1,250,000	$ 2,896,000		$ 2,896,000
Issuance of Series A convertible preferred stock, net of offering costs	9,647,000			9,647,000
Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock offering	(5,039,000)			(5,039,000)
Beneficial conversion feature arising from Series A convertible preferred stock	(4,436,000)			(4,436,000)
Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock	4,436,000			4,436,000
Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision	8,654,000			8,654,000
Impact of anti-dilution protection on liability-classified warrants	(491,000)			(491,000)
Convertible preferred stock dividends	(487,000)			(487,000)
Issuance of common stock in connection with warrant exchange agreements (in shares)			54,343
Issuance of common stock in connection with warrant exchange agreements	285,000			285,000
Issuance of common stock upon exercise of pre-funded warrants			4,049,783
Stock-based compensation	395,000			395,000
Net loss	(27,670,000)				(27,670,000)
Ending balance (in shares) at Dec. 31, 2018		0	22,026,476
Ending balance at Dec. 31, 2018	$ 5,245,000	$ 0	$ 2,000	$ 87,098,000	$ (81,855,000)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (27,670)	$ (23,754)
Adjustment to reconcile net loss to net cash used in operating activities:
Gain on extinguishment of debt	(766)	0
Non-cash In-process research and development impairment charge	9,100	0
Non-cash interest expense	134	0
Amortization of research and development expense	0	258
Deferred income taxes	(1,316)
Non-cash stock-based compensation	395	3,169
Fair value of common stock issued in exchange for services	0	449
Fair value of common stock issued in connection with litigation settlements	1,250	0
Fair value of common stock issued in connection with litigation settlements	0	941
Change in fair value of common stock warrants	(5,302)	0
Change in fair value of contingent consideration	3,032	0
Loss on settlement of liability-classified warrants	727	0
Severance costs paid by Galena	0	1,883
Changes in operating assets and liabilities:
Prepaid expenses and other assets	212	73
Accounts payable	(7,936)	8,366
Accrued expenses and other current liabilities	(2,282)	(2,374)
Net cash used in operating activities	(30,422)	(10,989)
Cash flows from investing activities:
Net cash acquired from acquisition of Galena	0	12,158
Net cash used from investing activities	0	12,158
Cash flows from financing activities:
Proceeds from issuance of Series A convertible preferred stock and common stock warrants, net of issuance costs	9,647	0
Proceeds from issuance of common stock, net of issuance costs	21,564	6,007
Dividends paid	(487)	0
Principal payments on long-term debt	(7,601)	(473)
Net cash provided by financing activities	23,123	5,534
Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents	(7,299)	6,703
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period	12,750	6,047
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period	5,451	12,750
Supplemental disclosure of cash flow information:
Cash received during the periods for interest	186	0
Cash paid during the periods for interest	321	0
Supplemental disclosure of non-cash investing and financing activities:
Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock recorded as issuance cost	5,530
Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock	4,436	0
Repayment of interest and principal on long-term debt through issuance of common stock	3,721	0
Reclassification of warrant liabilities upon exchange for shares of common stock	285	0
Impact of anti-dilution protection on liability-classified warrants	491	0
Debt issued in connection with warrant exchange agreements	966	0
Shares issued in connection with acquisition of Galena	0	12,487
Fair value of options assumed in connection with acquisition of Galena	0	32
Related party payable settled in shares	0	228
Memorial Sloan Kettering Cancer Center payable settled in shares	0	150
Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria	0	675
Convertible Debt Two Thousand Fifteen Shareholder Notes
Supplemental disclosure of non-cash investing and financing activities:
Stock issued	0	1,294
Convertible Debt Two Thousand Sely Note
Supplemental disclosure of non-cash investing and financing activities:
Stock issued	$ 0	$ 6,064

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Organization and Description of Business	Organization and Description of Business Overview SELLAS Life Sciences Group, Inc. (the "Company," or “SELLAS”) is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of indications. Merger of Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd. As used in this annual report on Form 10-K, the words the “Company,” and “SELLAS” refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"). This business combination is referred to as the Merger. On December 29, 2017, Galena completed the Merger with SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August 7, 2017 and amended November 5, 2017 (the "Merger Agreement"), among the Galena, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. As a result of the Merger, the Company’s business is now substantially comprised of the business of Private SELLAS, and although the Company is considered the legal acquiror of Private SELLAS, for accounting purposes, Private SELLAS is considered to have acquired the Company in the Merger. Consequently, the Merger was accounted for as a reverse acquisition and the Private SELLAS financial statements became the Company's financial statements. Immediately prior to the Merger, Galena effected a 1 -for- 30 reverse stock split of its outstanding common stock, par value $0.0001 per share. Under the terms of the Merger Agreement, Galena issued shares of its common stock to Private SELLAS’ securityholders at an exchange ratio of 43.9972 shares of its common stock in exchange for each common share of Private SELLAS outstanding immediately prior to the Merger. The Company also assumed all of the restricted stock units (“RSUs”) issued and outstanding under the Private SELLAS Stock Incentive Plan #1, and all of the issued and outstanding warrants of Private SELLAS. Accordingly, such RSUs will now be settled in, and such warrants now are exercisable for, shares of the Company’s common stock. Accordingly, immediately after the Merger, there were 5,766,891 shares of the Company’s common stock outstanding, with the former Private SELLAS securityholders owning 67.5% of the Company’s fully diluted common stock, and the Company’s pre-Merger securityholders owning the remaining 32.5% . The number of shares and per share amounts of common stock in the accompanying consolidated financial statements and notes to the consolidated financial statements have been restated to give retroactive effect to the common stock conversion ratio and reverse stock split for all periods presented, including common stock options, RSUs, and common stock warrants. Upon completion of the Merger, the Company’s name changed from “Galena Biopharma, Inc.” to “SELLAS Life Sciences Group, Inc.," the Company’s financial statements became those of Private SELLAS, and the Company's common stock began trading on The Nasdaq Capital Market under the new ticker symbol “SLS” on January 2, 2018.

Liquidity

Liquidity	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	Liquidity The Company has not generated any revenues, including from product sales, and has funded operations primarily from the proceeds of sales of its equity interests and convertible notes, as well as through the Merger. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company’s research and development efforts will be successful. On July 16, 2018, the Company completed an underwritten public offering (the "July 2018 Offering"), and issued (i) 6,845,000 shares of common stock, (ii) 4,675,000 pre-funded warrants exercisable for shares of common stock and (iii) accompanying common stock warrants to purchase an aggregate of 11,520,000 shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of $2.10 per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of $2.0999 per pre-funded warrant and common stock warrant. Each common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase one share of the Company’s common stock at an exercise price of $2.10 per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, five years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of $0.0001 per share, and will expire on July 16, 2023, five years from the date of issuance. The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other offering expenses, and excluding the exercise of any warrants, were approximately $21.6 million . In addition to the proceeds from the July 2018 Offering, on March 7, 2018, the Company entered into a securities purchase agreement to issue shares of its Series A convertible preferred stock (“Series A Convertible Preferred”) and warrants to purchase shares of its common stock in a private placement transaction to a select group of institutional investors. The sale of the aggregate 10,700 shares of Series A Convertible Preferred and 5.5 year warrants to acquire an aggregate of 1,383,631 shares of common stock at $6.59 per share was completed in two tranches and resulted in aggregate gross proceeds to the Company of approximately $10.7 million . The Company completed the first tranche for approximately $6.0 million gross proceeds on March 9, 2018. The Company completed the second tranche of the remaining $4.7 million gross proceeds on May 1, 2018, following stockholder approval. The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently, consider various other strategic alternatives, including a merger or sale of the Company, or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process. In February 2019, the Company engaged Cantor Fitzgerald & Co. to explore a wide range of strategic alternatives to continue the Company's business plan, with the ultimate objective being an outcome that is in the best interest of the Company's shareholders. Such alternatives may include, but are not limited to, a sale of the Company, a business combination, a merger or reverse merger with another company, a strategic investment into the Company, a sale, license or other disposition of corporate assets, a funded collaboration or partnership, or a financing which would allow the Company to continue with its current business plan of developing its development plans for its lead product candidates. To the extent that this engagement results in a transaction, our business objectives may change depending upon the nature of the transaction. There can be no assurance that we will enter into any transaction as a result of the engagement. The Company has evaluated the guidance of Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern , in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year from the date its financial statements are available to be issued. The Company has prepared its consolidated financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its product candidates, which raises substantial doubt about the Company’s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company’s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company’s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. As of December 31, 2018 , the Company had cash and cash equivalents of $5.3 million and a restricted cash balance of $0.1 million . In addition, the Company had outstanding accounts payable and accrued expenses of $6.0 million as of December 31, 2018 . The Company expects its existing cash as of December 31, 2018 , together with the gross proceeds of up to $4.2 million the Company may receive in connection with the exercise of certain warrants to purchase shares of common stock beginning in March 2019, pursuant to a warrant exercise agreement, will enable the Company to fund its operating expenses through June 2019. In the event that not all of the warrants subject to the warrant exercise agreement are exercised, the Company will need to raise additional capital earlier than anticipated to fund our operations.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). Principles of Consolidation The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and our wholly owned subsidiaries, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Private SELLAS, SLSG US, Inc., Sellas Life Sciences Limited, Sellas Life Sciences Group UK Ltd., Apthera, Inc., and Mills Pharmaceuticals, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar. Use of Estimates The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, beneficial conversion features associated with convertible notes, fair value of intangible assets acquired, carrying value of goodwill, fair value of contingent purchase price consideration, fair value of deferred tax liability assumed and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates. Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. The carrying amounts of the Company’s convertible notes that were outstanding as of December 31, 2017 approximate fair value due to the debt carrying a variable interest rate that is tied to the current London Interbank Offer Rate (“LIBOR”) rate. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level 3 of the fair value hierarchy. The fair value of the warrants is determined using a Black-Scholes pricing model. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits. Cash and Cash Equivalents The Company considers any highly liquid investments, such as money market funds, with an original maturity of three months or less to be cash and cash equivalents. Restricted Cash and Cash Equivalents Restricted cash consists of the minimum cash covenant as required by the debenture (see Note 9) and certificates of deposit on hand with the Company’s financial institutions as collateral for its corporate credit cards. Intangible Assets Intangible assets are comprised of identifiable in-process research and development (“IPR&D”) assets and are considered indefinite-lived intangible assets and are assessed for impairment annually on October 1 or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss. In the fourth quarter of 2018, the Company abandoned future development efforts for the IPR&D asset associated with the GALE-401 product candidate and recorded an impairment charge of $9.6 million , which was equal to the acquired value of GALE-401 of $9.1 million plus $0.5 million recorded as deposits and other assets related to upfront milestone payments. For those compounds that reach commercialization, the IPR&D assets will be amortized over their estimated useful lives. See Note 5 for further discussion of the Company's intangible assets. Goodwill Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit. The Company performs its annual goodwill impairment test at the reporting unit level on October 1 of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. Goodwill is evaluated for impairment using the simplified test of goodwill impairment as defined by FASB ASU No. 2017-04. Under the new guidance, goodwill impairment will be measured by the amount by which the carrying value of a reporting unit exceeds its fair value, without exceeding the carrying amount of goodwill allocated to that reporting unit. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit’s goodwill is less than the carrying value of the reporting unit’s goodwill. The Company did not recognize any impairment of goodwill during the years ended December 31, 2018 and 2017. Severance Costs Related to Merger The Company recognized and paid $1.9 million of exit costs during 2017 related to severance benefits for certain former Galena employees terminated immediately prior to the consummation of the Merger. Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred. Legal Fees and Insurance Recoveries There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal fees are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable. Stock-based Compensation The Company follows the provisions of the FASB ASC Topic 718, “ Compensation— Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (“ASC 505-50”), “ Equity Based Payments to Non-Employees .” Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. Clinical study costs, a component of research and development expenses, are accrued over the service periods specified in the contracts and adjusted as necessary based on an ongoing review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as research and development expenses. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. Research and development expenses primarily consist of the intellectual property and research and development materials acquired, expenses from third parties who conduct research and development activities on behalf of the Company as well as related wages, benefits and other operating costs. The Company expenses in-process research and development projects acquired as asset acquisitions which have not reached technological feasibility and which have no alternative future use. Income Taxes The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than not to be sustained. The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASBASC 740-10, “ Accounting for Income Taxes” (“ASC740-10”). These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. ASC740-10 requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company’s income tax provision or benefit. The recognition and measurement of benefits related to the company’s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company’s assumptions or changes in the Company’s assumptions in future periods are recorded in the period they become known. On December 22, 2017 the President of the United States signed into law the Tax Cuts and Jobs Act (the “2017 Tax Act”). This legislation makes significant changes in the United States tax laws including, but not limited to, reducing the corporate tax rate to 21% starting in 2018. The 2017 Tax Act required the Company to revalue its deferred tax assets and liabilities to the new rate of 21%. For the years ended December 31, 2018 and December 31, 2017, the Company recognized an income tax benefit of $1.4 million and an income tax expense of $0.3 million , respectively. Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Act. December 22, 2018 marked the end of the measurement period for purposes of SAB 118. As such, the Company completed the analysis based on legislative updates relating to the Act currently available, and no material adjustments have been recorded as of December 31, 2018. Net Loss Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive. The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands): Year Ended December 31, 2018 2017 Common stock warrants 17,698 963 Stock options 395 10 Unvested restricted stock awards 13 13 18,106 986 Comprehensive Loss The Company has no items of comprehensive income or loss other than net loss. Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity. Convertible Instruments The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument. The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock. Recent Accounting Pronouncements Pending Adoption In August 2018, FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement . ASU 2018-13 modifies, adds and removes certain specific the disclosure requirements on fair value measurements in Topic 820 . The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Accounting , which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both non-employees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (i) liability-classified nonemployee awards that have not been settled as of the adoption date and (ii) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-07 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures. In February 2016, the FASB issued ASU No. 2016-02 , Leases . In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases , and No. 2018-11, Leases (Topic 842) - Targeted Improvements . The new standard establishes a right-of-use , or ROU , model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU No. 2016-02 is effective for interim and annual periods beginning after December 15, 2018, and the Company adopted the standard effective January 1, 2019. The standard requires the use of a modified retrospective transition approach, applying the new standard to all leases existing at the adoption date. The Company estimates that the adoption of the standard will result in the recognition of an ROU asset and lease liability of approximately $0.5 million . Recent Accounting Pronouncements Adopted In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash . ASU No. 2016-18 requires that restricted cash be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows. In accordance with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. The Company's consolidated statement of cash flows for the year ended December 31, 2017 was reclassified to to conform to the current year presentation. The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands): December 31, 2018 2017 Cash and cash equivalents $ 5,337 $ 2,319 Restricted cash and cash equivalents 114 10,431 Total cash, cash equivalents, restricted cash, and restricted cash equivalents $ 5,451 $ 12,750 In connection with the Company's Senior Secured Debenture described in Note 9, the Company was required to maintain a minimum of the lesser of $18.5 million or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December 31, 2017, the Company maintained $10.2 million of cash and cash equivalents in a restricted account. The Senior Secured Debenture was no longer outstanding as of December 31, 2018 . In addition, the Company maintained $0.1 million and $0.2 million as of December 31, 2018 and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards. In May 2017, the FASB issued ASU No. 2017-09, Scope of Modification Accounting . ASU No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's consolidated financial statements.

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Acquisition	Acquisition On December 29, 2017, the Company completed the Merger with Private SELLAS as discussed in Note 1. The Merger was accounted for as a reverse merger under the acquisition method of accounting, whereby Private SELLAS was considered to have acquired the Company for financial reporting purposes because, immediately upon completion of the Merger, Private SELLAS stockholders held a majority of the voting interest of the combined company. The purchase consideration in a reverse acquisition is determined with reference to the value of equity that the accounting acquirer, in this case, Private SELLAS, would have had to issue to the owners of the accounting acquiree, the Company, to give the pre-acquisition equity holders of the Company the same percentage interest in Private SELLAS that such pre-acquisition equity holders held in the Company immediately following the Merger. The purchase price was calculated as follows (in thousands): Fair value of the Company's pre-Merger shares outstanding $ 12,487 Estimated fair value of the Company's pre-Merger stock options outstanding 32 Total purchase price $ 12,519 The Merger transaction has been accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands): Assets acquired: Cash $ 1,812 Restricted cash 10,346 Prepaid expenses and other assets 3,103 Intangible assets 17,600 Goodwill 1,914 Total assets acquired $ 34,775 Liabilities assumed: Accounts payable and accrued expenses $ 5,692 Litigation settlement 1,300 Long-term debt 10,988 Contingent purchase price consideration of Apthera, Inc. 1,294 Warrant liability 1,309 Deferred tax liability 1,673 Total liabilities assumed $ 22,256 Net assets acquired $ 12,519 Qualitative factors supporting the recognition of goodwill due to the Merger include the Company’s anticipated enhanced ability to secure additional capital and gain access to capital market opportunities as a public company. The goodwill is not deductible for income tax purposes. The following summary pro forma consolidated financial information reflects the Merger with Galena as if it had occurred on January 1, 2017 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company’s results of operations would have been had the Merger in fact occurred on January 1, 2017, and is not intended to project the Company’s results of operations for any future period. Year Ended December 31, 2017 Net loss (in thousands) $ (24,089 ) Basic and diluted net loss per share $ 5.15 Non-recurring pro forma transaction costs directly attributable to the Merger were $5.7 million for the year ended December 31, 2017 and have been deducted from the net loss presented above. The costs deducted from the year ended December 31, 2017 period included a success fee and other transaction costs of $4.8 million and issued 119,672 shares of common stock with a fair value of $0.9 million as a fee to Equilibria Capital Management Limited (“Equilibria”). Additionally, the Company incurred approximately $1.9 million in severance costs as a result of resignations of executive officers immediately prior to the Merger. These costs are excluded from the pro forma financial information for the year ended December 31, 2017. The Company excluded a $5.2 million impairment charge incurred by the Company as well as combined transaction costs from Galena and the Company in the amount of $8.7 million from the pro forma financial information for the year ended December 31, 2017.

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Notes)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The Company completes its annual impairment test on October 1 each year, or more frequently if triggering events indicate a possible impairment. The Company continually evaluates financial performance, economic conditions and other relevant developments in assessing if an interim period impairment test is necessary. The Company's goodwill balance at December 31, 2018 and 2017 was $1.9 million . Intangible assets consist of IPR&D acquired as part of the Merger. IPR&D assets represent research and development assets that have not yet reached commercialization. The Company's intangible assets consist of the following: Year Ended December 31, 2018 2017 NPS $ 5,700 $ 5,700 GALE-401 — 9,100 GALE-301 and GALE-302 2,800 2,800 $ 8,500 $ 17,600 The Company's IPR&D assets consist of the NPS program for the prevention of cancer recurrent in breast cancer patients, and the GALE-301 and GALE-302 programs for the prevention of cancer recurrent in ovarian and endometrial cancer patients in the adjuvant setting. In the fourth quarter of 2018, the Company abandoned future development efforts for the IPR&D asset associated with the GALE-401 product candidate and recorded an impairment charge of $9.6 million , which was equal to the acquired value of GALE-401 of $9.1 million plus $0.5 million recorded as deposits and other assets related to upfront milestone payments associated with that product candidate. The abandonment also resulted in an income tax benefit of $1.4 million .

Collaboration and License Agree

Collaboration and License Agreements	12 Months Ended
	Dec. 31, 2018
License Agreements [Abstract]
Collaboration and License Agreements	Collaboration and License Agreements As part of its business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed asset through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the Company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period. These arrangements sometimes permit the Company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. Memorial Sloan Kettering Cancer Center On September 4, 2014, (the “MSK Effective Date”) the Company entered into a license agreement (the “Original MSK License Agreement”) with MSK under which the Company was granted an exclusive license to develop and commercialize MSK’s WT1 peptide vaccine technology. Under the terms of the Original MSK License Agreement, the Company is required to obtain certain levels of financing. If such financing is not met, MSK will have the right to terminate the Original MSK License Agreement with prior written notice, unless the Company manages to overcome the shortfall during the term of the notice period. As part of the consideration for the rights, privileges and licenses granted under the Original MSK License Agreement, the Company issued 13,199 shares to MSK representing 1.5% of the Company’s fully diluted share capital as of the MSK Effective Date, which obligation was satisfied by assignment of 6,599 shares from each of the Company’s President, Chief Executive Officer, and co-founder, Dr. Angelos M. Stergiou, and the Company’s other co-founder, Dr. Miltiadis Sougioultzoglou (M.D.), to MSK, for which they received no consideration. Additionally, the Company was obligated to pay upfront license fees in an amount equal to $1.3 million . The Company recognized this amount as research and development expense during the year ended December 31, 2014, as it had no alternative future use. The Company would further be obligated to pay minimum royalty payments in the amount of $0.1 million each year commencing in 2015 and research funding costs of $0.2 million in each year and for three years commencing in January 2015. In addition, to the extent certain development and commercial milestones are achieved, the Company will be required to pay MSK up to $17.4 million in milestone payments for each licensed product, in addition to royalties in the event of commercial sales of any licensed products. The Original MSK License Agreement, unless terminated earlier in accordance with the terms of the Original MSK License Agreement, will continue on a country-by-country and licensed product-by-licensed product basis, until the later of: (i) expiration of the last valid claim embracing such licensed product; (ii) expiration of any market exclusivity period granted by law with respect to such licensed product; or (iii) ten ( 10 ) years from the first commercial sale in such country. On October 30, 2015, the Company and MSK entered into the License Amendment, Waiver and Share Issuance Agreement (the “First MSK Amendment”). The First MSK Amendment extended the date required for the Company to obtain financing from August 1, 2015 to December 31, 2016, modified the amount of required financing and waived past non-compliance with certain related provisions of the Original MSK License Agreement. In exchange for the First MSK Amendment, the Company agreed to issue an aggregate of 10,867 shares to MSK, which represented 1% of the fully diluted share capital of the Company at such date. The First MSK Amendment added certain anti-dilution protection clauses and entitled MSK to additional shares to the extent the Company was not able to obtain the required financing. On August 10, 2016, the Company and MSK entered into the Second License Amendment, Waiver and Agreement (the “Second MSK Amendment”). The Second MSK Amendment extended further the date required for the Company to obtain financing from December 31, 2016 to June 30, 2017, amended the anti-dilution provisions of the First MSK Amendment and waived past non-compliance with certain related provisions of the First MSK Amendment. Under the Second MSK Amendment, outstanding obligations of the Company to MSK in an amount of $0.9 million were converted into 13,815 shares effective November 1, 2016 upon the Company’s re-domiciliation to Bermuda. In consideration for this amendment and pursuant to the anti-dilution provisions in the Original MSK License Agreement as amended by the First MSK Amendment and the Second MSK Amendment, the Company issued MSK 30,314 additional shares and incurred accordingly $2.0 million of research and development expense, which reflected the fair value of the Company’s shares at such date. On May 25, 2017, the Company and MSK entered into an Amended and Restated Exclusive License Agreement (the “MSK A&R License Agreement”). Under the MSK A&R License Agreement, the Company expanded its license under the original MSK License Agreement, as amended, to include a license to commercially develop certain additional WT1 peptides through a program of exploiting certain patents and other rights covering such peptides. The MSK A&R License Agreement, among other changes, added certain milestone payments for each additional patent licensed product as defined in the MSK A&R License Agreement, and amended the milestone payments due upon commencement of the Phase 3 AML and mesothelioma clinical trials from $0.3 million to $0.4 million . In consideration for the MSK A&R License Agreement, the Company issued 8,799 shares to MSK. Pursuant to a side letter to the MSK A&R License Agreement, dated May 25, 2017 (the “MSK Side Letter”), MSK converted the next milestone payment of $0.2 million , which was due June 30, 2017, into shares. Further, in consideration for the MSK Side Letter, Dr. Stergiou, the Company’s Chief Executive Officer, assigned 15,399 of his shares to MSK, for which Dr. Stergiou received no cash consideration. On October 11, 2017, the Company and MSK entered into a second Amended and Restated Exclusive License Agreement (the “Second MSK A&R License Agreement”). Under the Second MSK A&R License Agreement, the Company and MSK extended the dates for the Company to have obtained necessary financing, and certain milestone dates, in exchange for increased milestone payments, clarification regarding MSK’s anti-dilution rights, and termination of the MSK Side Letter dated May 25, 2017. In connection with the Second MSK A&R License Agreement, the Company issued 74,795 shares to MSK. Prior to the Merger, the Company issued an additional 7,700 shares to MSK in connection with their anti-dilution rights. For the year ended December 31, 2018 the Company incurred $1.0 million of expenses relating to $0.5 million of milestone payments, $0.3 million in licensing fees, $0.1 million of guaranteed minimum royalty payments and $0.1 million of research funding costs. For the year ended December 31, 2017, the Company incurred $1.0 million of expenses relating to $0.7 million of milestone payments, $0.1 million of guaranteed minimum royal payments and $0.2 million of research funding costs. Such expenses have been included in research and development costs. Further, under the Second MSK Amendment, the Company is obligated to pay MSK $0.7 million in milestone payments in two equal installments, within 60 days following the initiation of its Phase 3 AML and mesothelioma clinical studies. Merck & Co., Inc. On September 21, 2017, the Company entered into a clinical trial collaboration and supply agreement through a Merck & Co., Inc. subsidiary, Merck Sharp & Dohme B.V. (“Merck subsidiary”), whereby the Company agreed with the Merck subsidiary to collaborate in a research program to evaluate GPS as it is administered in combination with Merck’s PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including both hematologic malignancies and solid tumors. The Phase 1/2 clinical trial will utilize a combination of GPS plus pembrolizumab in patients with WT1+ relapsed or refractory tumors. Specifically, the study is expected to explore the following cancer indications: AML, ovarian, triple-negative breast, small cell lung, and colorectal (arm enriched in but not exclusive to patients with microsatelite instability-low tumors). This study will assess the efficacy and safety of the combination, comparing overall response rates and immune response markers achieved with the combination compared to prespecified rates based on those seen with pembrolizumab alone in comparable patient populations. This trial was initiated in December 2018. Advaxis, Inc. On February 24, 2017, the Company and Advaxis, Inc. (“Advaxis”) entered into a research and development collaboration agreement, whereby both parties will collaborate in a research program to evaluate, through a “proof of principle” trial or trials (“PoP Clinical Trial”), a clinical candidate comprised of the combination of Advaxis’ proprietary Lm- based antigen delivery technology and the Company’s patented WT1 targeted heteroclitic peptide antigen mixture (GPS). The term of the Advaxis agreement will expire upon the earlier of: (a) completion of the PoP Clinical Trial, (b) a decision by the parties to cease further development of the clinical candidate and (c) early termination of the Advaxis agreement pursuant to the terms thereof. The Advaxis agreement provides for cost-sharing between the parties, with Advaxis being responsible for the costs of performing the research activities and filing any investigational new drug application (“IND”), cost-sharing for preparation of the IND, and the Company being responsible for the costs (exclusive of product costs) of conducting the PoP Clinical Trial. The Company also agreed to make certain non-refundable milestone payments to Advaxis having an aggregate amount of up to $108.0 million , upon meeting certain clinical, regulatory and commercial milestones. In addition, if net sales exceed certain targets, the Company agreed to make non-refundable sales milestone payments up to $250.0 million and royalty payments based on specific royalty rates, with a maximum rate capped at a percentage rate in the low double digits if net sales exceed $1.0 billion . The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. On September 11, 2006, the Company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (“MDACC”) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (“HJF”) which grants exclusive worldwide rights to a United States patent covering the nelipepimut-S peptide vaccine ("NPS") and several United States and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, the Company is required to pay an annual maintenance fee of $0.2 million , up to $3.8 million for clinical milestone payments, and to pay a tiered royalty in the mid-single digits based on sales of NPS or other therapeutic products developed from the licensed technologies.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands): Description December 31, 2018 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Cash equivalents $ 5,195 $ 5,195 $ — $ — Total assets measured and recorded at fair value $ 5,195 $ 5,195 $ — $ — Liabilities: Warrants potentially settleable in cash $ 1,013 $ — $ — $ 1,013 Contingent consideration 4,326 — — 4,326 Total liabilities measured and recorded at fair value $ 5,339 $ — $ — $ 5,339 Description December 31, 2017 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Cash equivalents $ 1,662 $ 1,662 $ — $ — Restricted cash equivalents 10,245 10,245 — — Total assets measured and recorded at fair value $ 11,907 $ 11,907 $ — $ — Liabilities: Warrants potentially settleable in cash $ 1,309 $ — $ — $ 1,309 Contingent consideration 1,294 — — 1,294 Total liabilities measured and recorded at fair value $ 2,603 $ — $ — $ 2,603 The Company did not transfer any financial instruments into or out of Level 3 classification during the years ended December 31, 2018 and 2017 . See Note 12 for a reconciliation of the changes in the fair value of the warrant liability for the years ended December 31, 2018 . A reconciliation of the change in the fair value of the contingent consideration liability for the years ended December 31, 2018 and 2017 is as follows (in thousands): Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Contingent consideration, January 1, 2017 $ — Contingent consideration acquired as part of the Merger 1,294 Contingent consideration, December 31, 2017 $ 1,294 Change in the estimated fair value of the contingent consideration 3,032 Contingent consideration, December 31, 2018 $ 4,326 The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena’s acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to $32.0 million based on the achievement of certain development and commercial milestones relating to NPS. The contingent consideration is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval of its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The change in the estimated fair value of the contingent consideration during the year ended December 31, 2018 reflects an adjusted probability and timeline for the potential approval of NPS associated with the positive interim data in the triple-negative breast cancer cohort from the prospective, randomized, single-blinded, controlled Phase 2b investigator-sponsored clinical trial of trastuzumab (Herceptin®) +/- NPS in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences that was announced on April 2, 2018.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands): December 31, 2018 December 31, 2017 Professional fees $ 540 $ 1,744 Compensation and related benefits 675 566 Clinical trial costs 858 51 Value-added tax — 426 Rebates and returns of former commercial products 138 223 Other 8 191 Accrued expenses and other current liabilities $ 2,219 $ 3,201

Debt

Debt	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Debt	Debt The Company has no debt outstanding at December 31, 2018. Debt outstanding consisted of the following at December 31, 2017: December 31, 2017 Debt Current portion of Senior Secured Debenture $ 8,377 Non-current portion of Senior Secured Debenture 2,611 Total debt $ 10,988 Senior Secured Debenture On May 10, 2016, the Company's predecessor company, Galena, entered into a securities purchase agreement (the “Securities Purchase Agreement”) with JGB (Cayman) Newton, Ltd. ("JGB") pursuant to which Galena sold to JGB, at a 6.375% original issue discount, a $25.5 million senior secured debenture (the "Senior Secured Debenture") and warrants to purchase up to 3,333 shares of the Company's common stock. Net proceeds to Galena from the sale of the Senior Secured Debenture and warrants, after payment of commissions and legal fees, were approximately $23.4 million . The maturity date of the Senior Secured Debenture was November 10, 2018, with accrued interest at 9% per year, payable monthly. In addition, on the maturity date of the Senior Secured Debenture (or such earlier date that the principal amount of the Senior Secured Debenture is paid in full by acceleration or otherwise) a fixed amount, which would have been deemed interest under the Senior Secured Debenture, equal to $0.8 million was due and payable to JGB on such date in, at the option of the Company, cash and, subject to the same conditions for the payment of interest, in shares of the Company’s common stock, or a combination of cash and the Company’s common stock. The Company’s obligations under the Senior Secured Debenture were secured under a security agreement by a senior lien on all of the Company’s assets, including all of the Company’s interests in its consolidated subsidiaries. Private SELLAS was not a party to the security agreement. Under the terms of a subsidiary guarantee agreement, each subsidiary guaranteed the performance of the Company of the Securities Purchase Agreement, Senior Secured Debenture and related agreements. • The Company was required to maintain a minimum of the lesser of $18.5 million or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were transferred to the Company's unrestricted account to fund its ongoing operations. As of December 31, 2017 , the Company maintained $10.2 million of cash and cash equivalents in a restricted account. As of December 31, 2017 , the outstanding principal balance of the Senior Secured Debenture was $10.2 million . In addition to the outstanding principal balance, the Senior Secured Debenture had $0.8 million of additional interest that was included in the current portion of long-term debt as of December 31, 2017 . During the year ended December 31, 2018 , JGB redeemed $2.8 million of outstanding principal, which the Company satisfied with 659,529 shares of its common stock and redeemed $0.6 million of outstanding principal, which the Company satisfied with cash. As a result of the redemptions during 2018, the Company transferred $1.8 million of restricted cash into unrestricted cash and cash equivalents, which was used to fund the Company’s ongoing operations. In April 2018, JGB commenced a lawsuit against the Company, as described in Note 10. On November 5, 2018, the parties to the JGB lawsuit entered into a settlement agreement, which required, among other things, that JGB make a one-time payment to the Company of $6.6 million , representing the $1.6 million excess cash removed from the amount in the restricted account from the outstanding principal balance of the Senior Secured Debenture and reimbursement of approximately $5.0 million of legal fees incurred by the Company. The Company recognized a gain on extinguishment of debt of $0.8 million that was previously accrued in long-term debt representing an additional interest payable at maturity as the amount is no longer required to be repaid by the Company. Accordingly, the Senior Secured Debenture is no longer outstanding and the related agreements have been terminated. Short-term Convertible Promissory Notes During the year ended December 31, 2018 , the Company issued convertible promissory notes in the principal amount of $1.0 million in exchange for the surrender and cancellation of warrants to purchase 412,667 shares of its common stock pursuant to the February 2017 public offering by Galena. The convertible promissory notes accrued interest at a rate of 5% per annum and were convertible into shares of the Company's common stock at a conversion price equal to $7.00 . In April 2018, $0.8 million of outstanding principal and accrued interest was converted into 118,644 shares of common stock. In November of 2018, the Company paid the remaining principal and interest of $0.2 million to settle the debt. As of December 31, 2018 , there was no principal balance and accrued interest outstanding.

Legal Proceedings, Commitments

Legal Proceedings, Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings, Commitments and Contingencies	Legal Proceedings, Commitments and Contingencies Legal Proceedings From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company’s consolidated results of operations, financial position or cash flows. The Company’s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal, some of which are ongoing and to which the Company is now subject as a result of the Merger. The Company is also involved in litigation matters as follows: On October 13, 2016, Galena filed a complaint against Aon Risk Insurance Services West, Inc. in the Circuit Court for Multnomah County, Oregon. The complaint seeks damages related to Galena’s coverage dispute with a certain insurer, including the amounts Galena was required to contribute to the settlements of In re Galena Biopharma, Inc. Derivative Litigation and In re Galena Biopharma, Inc. Securities Litigation as a direct result of certain insurer’s failure to pay its full policy limits. On November 30, 2018, the Company amended its complaint to seek punitive damages. Trial is scheduled to begin on May 6, 2019. On February 13, 2017, certain putative shareholder securities class action complaints were filed in federal court alleging, among other things, that the Company and certain of the Company's former officers and directors failed to disclose that Galena’s promotional practices for Abstral ® (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena’s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the U.S. District Court for the District of New Jersey and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint and on December 21, 2018, plaintiffs filed their opposition to the motion to dismiss. On January 18, 2019, the Company filed a reply in support of its motion. The Company's motion to dismiss the amended complaint is currently pending in the U.S. District Court for the District of New Jersey. In March 2017, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company’s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company’s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company’s former directors, officers and employees, and the Company as a nominal defendant. In June 2018, a derivative complaint was filed in the U.S. District Court for the Northern District of California against the Company’s current and former directors, and the Company as a nominal defendant. The plaintiff in the June 2018 case voluntarily withdrew his complaint from the U.S District Court of the Northern District of California and on August 27, 2018, refiled the complaint in the Court of Chancery of the State of Delaware. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company’s behalf against the Company’s former directors and, in certain of the complaints, the Company’s current directors, and the Company’s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The March 2017, July 2017, and January 2018 lawsuits are currently stayed pending resolution of motions to dismiss in the referenced securities class action. On November 15, 2018, the defendants in the August 2018 lawsuit filed a motion to dismiss the complaint. On December 17, 2018, the plaintiff filed an amended complaint. The defendants filed a motion to dismiss the amended complaint on January 31, 2019. In April 2017, a putative stockholder class action, captioned Patel vs. Galena Biopharma Inc. et. al, was filed in Delaware state court seeking relief under Section 225 of the Delaware General Corporation Law ("DGCL") and alleging breaches of fiduciary duties by Galena’s former board of directors and former interim chief executive officer regarding the proposals to amend Galena’s certificate of incorporation to increase the amount of authorized shares of common stock and effectuate a reverse stock split at the July 2016 and October 2016 stockholder meetings, respectively. On June 2, 2017, an amended verified complaint was filed along with a motion to expedite the proceedings. On July 24, 2017, Galena entered into a binding settlement term sheet, involving payment of $50,000 in cash and $1,250,000 in unrestricted shares of common stock. The Court enforced the settlement term sheet on November 30, 2017. On June 14, 2018, the Court entered an Order and Final Judgment approving the settlement and awarding attorneys’ fees to the plaintiff. All obligations related to the Order and Final Judgment were satisfied in full by the Company in June 2018. In October 2018, the Company received $0.5 million from its insurance carrier for previous amounts paid by the Company in excess of its retention amount and recorded the amount as a reduction to general and administrative expense in the Company's consolidated statement of operations. On or about April 9, 2018, JGB filed a lawsuit in the U.S. District Court for the Southern District of New York (the "Court") captioned JGB (Cayman) Newton, Ltd. v. Sellas Life Sciences Group, Inc., et al., Case 1:18-cv-3095 (DLC) (the "JGB Action"). The complaint in the JGB Action asserted claims under state law and federal securities law against the Company, the Company's Chief Executive Officer, Angelos M. Stergiou, M.D., ScD h.c., and the Company's former Interim Chief Financial Officer, Aleksey N. Krylov. On or about May 2, 2018, JGB filed an amended complaint, adding as defendants certain members of the Company's Board of Directors. On May 18, 2018, the Company filed an answer to the amended complaint and filed seven counterclaims. On June 18, 2018, the Company filed a motion for judgment on the pleadings and a motion to dismiss the amended complaint. On July 6, 2018, JGB filed a motion for partial judgment on the pleadings and motion to dismiss all of the Company's counterclaims. On September 24, 2018, without any prior written notice, JGB unilaterally directed that all of the funds, approximately $8.5 million in cash, be removed from the restricted account, an amount in excess of the outstanding principal balance of the Senior Secured Debenture. On October 23, 2018, the Court entered an Opinion and Order, granting, in full, the Company's motion to dismiss JGB's amended complaint and allowing four of the Company's counterclaims to proceed to trial. Following the October 23 Opinion and Order of the Court, the parties to the JGB Action entered into a settlement agreement on November 5, 2018. The settlement agreement provides, among other things, that JGB will make a one-time payment to the Company of $6.6 million , inclusive of the $1.6 million excess amount removed from the restricted account. The entire settlement amount was received in November 2018. The Company offset approximately $5.0 million of legal fees incurred during the year ended December 31, 2018 previously recorded in general and administrative expense in the consolidated statement of operations with proceeds from the settlement. The Company recognized a gain on extinguishment of debt of $0.8 million that was previously accrued in long-term debt for an additional interest payable at maturity as the amount is no longer payable by the Company. The settlement agreement also provides for the termination of the Senior Secured Debenture and all ancillary agreements, including the security agreement covering the Company's assets as well as a release of all security interests in the collateral. Contingent Consideration related to Development, Regulatory and Commercial Milestone Payments and Business Combinations The Company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is required to make royalty payments based upon a percentage of the sales. Because of the contingent nature of these payments, they are not included in the table of contractual obligations shown below. These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the Company the discretion to unilaterally terminate development of the product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. For additional information on the Company’s commitments under collaboration and license agreements read Note 6 to these consolidated financial statements. For additional information on the Company’s commitments of contingent consideration read Note 7 to these consolidated financial statements. Commitments The Company rents office space under a non-cancelable operating lease. Rental expense amounted to $0.3 million and $0.2 million for the years ended December 31, 2018 and 2017, respectively. The Company’s contractual obligations that may require future cash payments as of December 31, 2018 under the non-cancelable operating lease are as follows (in thousands): Amount 2019 $ 377 2020 224 Total $ 601

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred Stock The Company has authorized up to 5,000,000 shares of preferred stock, $0.0001 par value per share, for issuance. Series A Convertible Preferred On March 7, 2018, the Company entered into a securities purchase agreement with investors, pursuant to which the Company agreed to sell to the investors, in a private placement pursuant to Rule 4(a)(2) and Regulation S under the Securities Act, an aggregate of 10,700 shares of the Company’s newly-created non-voting Series A Convertible Preferred, and warrants to acquire an aggregate 1,383,631 shares of the Company’s common stock, par value $0.0001 per share at an aggregate purchase price of $10.7 million . The Series A Convertible Preferred was initially convertible into 1,844,835 shares of common stock based on an initial conversion price of $5.80 per share. At the first closing of the Series A Convertible Preferred on March 9, 2018, the Company issued an aggregate 5,987 shares of Series A Convertible Preferred and warrants to acquire 774,186 shares of common stock for aggregate gross proceeds of $6.0 million . The second closing of the remaining 4,713 shares of the Series A Convertible Preferred and warrants to acquire 609,445 shares of its common stock, for aggregate gross proceeds of $4.7 million , occurred on May 1, 2018 following receipt of stockholder approval. In the event of a "qualified offering," as defined in the securities purchase agreement, holders of the Series A Convertible Preferred (the "Series A Holders") had the right to exchange their shares of Series A Convertible Preferred for the same securities sold in a qualified offering on a $1.00 for $1.00 basis based on the stated value of their shares of Series A Convertible Preferred under the most favored nation provision. On July 16, 2018, following consummation of the July 2018 Offering, which was deemed a qualified offering as described below and in Note 2 above, the Series A Holders exchanged an aggregate of $7,871,186 of stated valued and accrued but unpaid dividends on their Series A Convertible Preferred for an aggregate of 3,748,184 shares of the Company’s common stock and warrants to purchase an aggregate of 3,748,184 shares of the Company’s common stock. Following such exchange, there are no shares of Series A Convertible Preferred issued and outstanding. The warrants have an exercise price of $2.10 per share and a term of five years. The fair value of the common stock and warrants to purchase shares of common stock exceeded the carrying amount of the Series A Preferred by $8.7 million and that amount is recorded as a deemed dividend in the consolidated statements of operations during the year ended December 31, 2018 , as it represents a transfer of value from the common stockholders to the preferred investors. Since the Company does not have accumulated earnings, the deemed dividend is taken from additional paid-in capital. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the year ended December 31, 2018 . In addition, pursuant to the terms of the warrants, the exercise price of the warrants issued to the investors in March 2018 and May 2018 was automatically adjusted to $2.10 per share from the original exercise price of $6.59 per share. The Company recognized the $0.5 million increase to the fair value of the warrant liability as a result of the adjusted stock price as a deemed dividend in the consolidated statements of operations during the year ended December 31, 2018 . This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the year ended December 31, 2018 . The Company evaluated the Series A Convertible Preferred in accordance with the provisions of ASC 815, Derivatives and Hedging , including consideration of embedded derivatives requiring bifurcation. The issuance of the Series A Convertible Preferred generated a beneficial conversion feature (“BCF”), which arose as the equity security was issued with an embedded conversion option that was beneficial to the investor or in the money at inception because the conversion option had an effective conversion price that was less than the market price of the underlying stock at the commitment date. The Company recognized the BCF by allocating the intrinsic value of the conversion option, which is the number of shares of common stock available upon conversion multiplied by the difference between the effective conversion price per share and the fair value of common stock per share on the commitment date, to additional paid-in capital, resulting in a discount on the convertible preferred stock. As the Series A Convertible Preferred could have been converted immediately, the Company recognized a BCF of $2.0 million as a deemed dividend in the consolidated statements of operations related to the first closing on March 9, 2018 and an additional BCF of $2.5 million as a deemed dividend related to the second closing on May 1, 2018. These one-time, non-cash charges impacted net loss attributable to common stockholders and loss per share for the year ended December 31, 2018 . Common Stock The Company has authorized up to 350,000,000 shares of common stock, $0.0001 par value per share, for issuance. On July 16, 2018, the Company completed the July 2018 Offering, issuing 6,845,000 shares of common stock and 4,675,000 pre-funded warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of 11,520,000 shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of $2.10 per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of $2.0999 per pre-funded warrant and common stock warrant. Each accompanying common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase one share of the Company’s common stock at an exercise price of $2.10 per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, five years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of $0.0001 per share, and will expire on July 16, 2023, five years from the date of issuance. The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants, were approximately $21.6 million . During its evaluation of equity classification for the pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued in the July 2018 Offering, the Company considered the conditions as prescribed within ASC 815-40, Derivatives and Hedging , Contracts in an Entity’s own Equity (“ASC 815-40”). The conditions within ASC 815-40 are not subject to a probability assessment. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480, Distinguishing Liabilities from Equity, as they are not puttable and do not represent an instrument that has a redeemable underlying security. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company’s own stock and would be classified in permanent equity if freestanding. Shares of common stock reserved for future issuance are as follows (in thousands): December 31, 2018 Warrants outstanding 17,698 Stock options outstanding 395 Options reserved for future issuance under the Company’s 2017 Equity Incentive Plan 421 Shares reserved for future issuance under the Employee Stock Purchase Plan 115 Restricted stock units 13 Total reserved for future issuance 18,642

Warrants to Acquire Shares of C

Warrants to Acquire Shares of Common Stock	12 Months Ended
	Dec. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Warrants to Acquire Shares of Common Stock	Warrants to Acquire Shares of Common Stock The following is a summary of the Company's warrants to acquire shares of common stock activity for the year ended December 31, 2018 (in thousands): Warrant Issuance Outstanding, December 31, 2017 Granted Exercised Canceled/Expired Outstanding, December 31, 2018 Expiration July 2018 Offering — 15,268 — — 15,268 July 2023 Pre-funded July 2018 Offering — 4,675 (4,050 ) — 625 July 2023 Series A Convertible Preferred — 1,384 — 1,384 September 2023 2017 Equilibria 316 — — 316 December 2022 Galena February 2017 567 — — (534 ) 33 February 2022 Galena Other 80 — — (8 ) 72 January 2022 963 21,327 (4,050 ) (542 ) 17,698 Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants. During the year ended December 31, 2018 , a total of 534,334 of the Galena February 2017 liability-classified warrants to purchase shares of common stock were canceled under various warrant exchange agreements. The Company issued 54,613 shares of its common stock in exchange for the surrender and cancellation of warrants to acquire 121,667 shares of its common stock and $1.0 million in convertible promissory notes in exchange for the surrender and cancellation of warrants to acquire 412,667 shares of its common stock, as described in Note 11. The fair value of the common stock and promissory notes exchanged totaled $1.2 million , which exceeded the fair value of the warrant liability of the warrants canceled by $0.7 million and is recorded as loss on settlement of liability-classified warrants in the consolidated statement of operations for the year ended December 31, 2018 . In April 2018, $0.8 million of outstanding principal and accrued interest was converted into 118,644 shares of common stock. Warrants Classified as Liabilities Liability-classified warrants consist of warrants to acquire common stock issued in connection with previous equity financings for the Series A Convertible Preferred, Galena's February 2017 offering, and various other Galena equity financings that were assumed by the Company at the consummation of the Merger. These warrants may be settled in cash and were determined to not be indexed to the Company’s common stock. Prior to the consummation of the July 2018 Offering, the initial exercise price of the warrants to acquire shares of common stock in connection with the Series A Convertible Preferred was $6.59 per share of common stock, subject to standard adjustments for certain transactions affecting the Company’s securities (such as stock dividends, and stock splits). From the original issue date until the one-year anniversary of a qualified offering, the initial exercise price and number of warrants to acquire shares of common stock are subject to anti-dilution protection in the event of non-exempt equity issuances at a price per share lower than the then exercise price (the "Base Share Price"). Simultaneously with the consummation of each non-exempt equity issuance the exercise price shall be reduced to equal the Base Share Price. Such adjustment shall be made whenever such common stock or common stock equivalents are issued. The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: As of December 31, 2018 Warrant Issuance Outstanding (in thousands) Strike price (per share) Expected term (years) Volatility % Risk-free rate % Series A Convertible Preferred 1,384 $ 2.10 4.76 88.80 % 2.50 % Galena February 2017 33 $ 33.00 3.12 94.12 % 2.46 % Galena Other 72 $ 829.88 2.43 94.73 % 2.46 % As of December 31, 2017 Warrant Issuance Outstanding (in thousands) Strike price (per share) Expected term (years) Volatility % Risk-free rate % Galena February 2017 567 $ 33.00 4.12 79.29 % 2.09 % Galena Other 76 $ 888.22 2.74 72.46 % 2.00 % The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero , because the Company has no present intention to pay cash dividends. The changes in fair value of the warrant liability for the year ended December 31, 2018 were as follows (in thousands): Warrant Issuance Warrant liability, December 31, 2017 Fair value of warrants granted Fair value of warrants canceled Adjustment to exercise price of warrants Change in fair value of warrants Warrant liability, December 31, 2018 Series A Convertible Preferred $ — $ 5,039 $ — $ 491 $ (4,520 ) $ 1,010 Galena February 2017 1,305 — (526 ) — (776 ) 3 Galena Other 4 — — — (4 ) — $ 1,309 $ 5,039 $ (526 ) $ 491 $ (5,300 ) $ 1,013 Warrants Classified as Equity The Company issued warrants to acquire 316,163 shares of the its common stock at an exercise price of $7.42 per share, maturing five years from issuance, to EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund on December 29, 2017. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods. The fair value of the warrants granted was $5.60 per share using the Black-Scholes pricing model with the fair value assumptions for the grant including a volatility of 90.10% , expected term of five years, risk free rate of 2.20% , and a dividend rate of 0.00 . The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued during the July 2018 offering are recorded in equity upon issuance as described in Note 11.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation Share and per share amounts below have been retroactively adjusted to reflect the exchange ratio and reverse stock split described in Note 1. 2017 Equity Incentive Plan On December 29, 2017, the 2017 Equity Incentive Plan was approved, and currently allows for the issuance of up to a maximum of approximately 1,686,000 shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, not including shares subject to awards assumed in connection with certain transactions, including the Merger. Upon the consummation of the Merger, the Company assumed approximately 10,171 shares subject to outstanding common stock options granted under the Company’s 2016 Incentive Plan that remained exercisable through December 29, 2018 for former Company employees and directors. The number of shares reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, for a period of not more than ten years, commencing on January 1, 2018 and ending on (and including) January 1, 2027, in an amount equal to 4% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. Notwithstanding the foregoing, the board of directors may act prior to January 1 of a given year to provide that there will be no January 1 increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. The number of shares reserved for issuance under the 2017 Equity Incentive Plan was automatically increased to approximately 1,686,000 on January 1, 2019. As of December 31, 2018 , an aggregate of approximately 381,000 shares of common stock were reserved for future grants under the Company’s 2017 Equity Incentive Plan. There were no common stock options granted under the 2017 Equity Incentive Plan for the year ended December 31, 2017. The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the years ended December 31, 2018 and 2017 , respectively (in thousands): Years Ended December 31, 2018 2017 Research and development $ 77 $ 729 General and administrative 318 2,440 Total stock-based compensation $ 395 $ 3,169 Options to Purchase Shares of Common Stock The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the weighted average fair value of all its stock options granted during the year ended December 31, 2018: Risk free interest rate 2.73 % Volatility 80.83 % Expected lives (years) 6.20 Expected dividend yield — % The weighted-average grant date fair value of options granted during the year ended December 31, 2018 was $3.73 . There were no stock options granted during the year ended December 31, 2017 . The Company’s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company’s options of ten years with the average vesting term of four years for an average of six years . The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero , because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur, therefore, outstanding stock options equal vested and expected to vest stock options. As of December 31, 2018 , there was $0.9 million of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company’s operating expenses over a weighted-average period of 2.13 years. The following table summarizes stock option activity of the Company for the year ended December 31, 2018: Total Number of Shares (In Thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (In Thousands) Outstanding at January 1, 2018 10 $ 1,240.55 1.00 $ — Granted 483 5.24 — Canceled (98 ) 5.30 $ — Outstanding at December 31, 2018 395 $ 37.09 9.01 $ — Options exercisable at December 31, 2018 53 $ 241.17 7.63 $ — The aggregate intrinsic values of outstanding and exercisable stock options at December 31, 2018 were calculated based on the closing price of the Company’s common stock as reported on the Nasdaq Capital Market on December 31, 2018 of $1.23 per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company’s common stock and the exercise price of the underlying stock options. RSUs with Time-Based and Performance-Based Conditions The Company granted RSUs subject to both time-based and performance-based vesting conditions to certain of its employees and non-employees pursuant to the 2016 Incentive Plan. These RSUs vest based on both (i) continued service either over a three -year measurement period or at the end of the required service period and (ii) the achievement of a liquidity event. The initial vesting date for these RSUs was February 27, 2018. The liquidity event, as defined in the relevant RSU grant agreements, will be satisfied upon the earlier of either: (a) change of control or (b) a qualified public offering. As of December 31, 2018 and December 31, 2017, there were approximately 13,000 RSUs outstanding with a weighted average grant date fair value of $52.94 . The Company recognizes compensation expense related to these RSUs when the liquidity event is deemed probable. As such, no compensation expense was recorded to date as the liquidity event is outside the Company’s control and not deemed probable until it occurs. 2017 Employee Stock Purchase Plan The Company also has an employee stock purchase plan (“ESPP”) which allows employees to contribute up to 15% of their cash earnings, subject to certain maximums, to be used to purchase shares of the Company’s common stock on each semi-annual purchase date. On each offering date, each eligible employee, pursuant to an offering made under the ESPP, will be granted a right to purchase up to that number of shares of common stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board of Directors, but in either case not exceeding fifteen percent ( 15% ) of such employee’s earnings (as defined by the Board of Directors in each offering) during the period that begins on the offering date (or such later date as the Board of Directors determines for a particular offering) and ends on the date stated in the offering, which date will be no later than the end of the offering. As of December 31, 2018, the Board of Directors has not established the various parameters under the ESPP and no shares have been delivered under the ESPP. There are approximately 265,000 shares of common stock reserved for issuance under the ESPP, plus the number of shares of common stock that are automatically added on January 1st of each year for a period of up to ten years, commencing on the first January 1, 2018 and ending on (and including) January 1, 2027, in an amount equal to the lesser of (i) 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, and (ii) 150,000 shares of common stock.

Income Taxes (Notes)

Income Taxes (Notes)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The loss before income taxes is as follows (in thousands): As of December 31, 2018 2017 U.S. $ (17,179 ) $ 265 Non - U.S. (11,869 ) (23,766 ) $ (29,048 ) $ (23,501 ) The components of federal and state income tax expense are as follows (in thousands): As of December 31, 2018 2017 Current Federal $ (106 ) $ 76 State 45 138 Foreign — — Total current (61 ) 214 Deferred expense Federal (747 ) — State (570 ) 39 Foreign — — Total deferred (1,317 ) 39 Total income tax expense $ (1,378 ) $ 253 The components of net deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2018 2017 Net operating loss carryforwards $ 4,464 $ 1,028 Tax credit carryforwards 134 345 Stock-based compensation 2,223 2,550 Licensing deduction deferral 5,961 2,105 Other 56 395 Gross deferred tax assets 12,838 6,423 Valuation allowance (11,410 ) (4,658 ) Net deferred tax asset $ 1,428 $ 1,765 The components of net deferred tax liabilities are as follows (in thousands): As of December 31, 2018 2017 In-process research and development not subject to future amortization for tax purposes $ 1,785 $ 3,438 Gross deferred tax liability $ 1,785 $ 3,438 The net deferred tax liabilities are as follows (in thousands): As of December 31, 2018 2017 Net deferred tax asset $ 1,428 $ 1,765 Gross deferred tax liability 1,785 3,438 Net deferred tax liability $ 357 $ 1,673 The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows: As of December 31, 2018 2017 U.S. federal statutory income tax rate (21.0 )% (34.0 )% State and local taxes, net of federal benefit (1.0 )% 0.4 % Foreign rate differential 8.6 % 34.4 % Permanent differences (1.5 )% 1.1 % Tax rate change and true-up (13.9 )% 0.3 % Other 0.1 % 0.2 % Valuation allowance 23.5 % 0.1 % Tax credits 0.5 % (1.4 )% Effective income tax rate (4.7 )% 1.1 % At December 31, 2018, the Company had domestic federal and state net operating loss carryforwards of approximately $19.7 million and $3.7 million , respectively, available to reduce future taxable income, which expire beginning in 2027. The Company also had federal research and development tax credit carryforwards of approximately $0.1 million , available to reduce future tax liabilities and which expire at various dates beginning in 2035. The income tax expense for the year ended December 31, 2018 and 2017 relates to both the indefinite lived deferred tax liabilities and the December 22, 2017 enactment of the Tax Cuts and Jobs Act. Under the provisions of the Internal Revenue Code, the net operating losses (“NOL”) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% , as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the amount of tax attributes that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financings since its inception, which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. Utilization of the net operating loss and tax credits carryforwards may be limited by “ownership change” rules, as defined in Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. In assessing the need for a valuation allowance the Company may utilize indefinite-lived deferred tax liabilities from an indefinite-lived intangible asset as a future source of income. The Company’s IPR&D, as recorded in acquisition accounting, can be utilized as a source of income arising from the future reversal of temporary difference that can be offset against post 2017 indefinite-lived NOLs. Therefore, the Company is permitted to offset the indefinite-lived DTL up to the 80 percent limitation for NOL’s generated subsequent to January 1, 2018. The valuation allowance increased by $1.4 million for the year ended December 31, 2018 as a result of the impairment of one of the Company's indefinite-lived intangible assets and changes in the Company's state apportionment. The Company files income tax returns in the United States and various state jurisdictions. The Company is subject to tax examinations for the 2014 tax year and beyond. The Company does not recognize tax benefits that are not more-likely-than-not to be supported based upon the technical merits of the tax position taken. In assessing its unrecognized tax benefits, the Company has analyzed its tax return filing positions in all of the federal, state and foreign filing jurisdictions where it is required to file income tax returns, as well as all open years in those jurisdictions. The following table indicates the changes to the Company’s unrecognized tax benefits (in thousands): As of December 31, 2018 2017 Beginning of the Year - unrecognized tax benefits $ 72 $ — Increase/(Decrease) - prior year tax positions (17 ) 44 Increase - current year tax positions — 28 End of the Year - unrecognized tax benefits $ 55 $ 72 The unrecognized tax benefits, if recognized and in absence of full valuation allowance, would impact the income tax provision by $55,000 and $72,000 as of December 31, 2018 and 2017, respectively. As of December 31, 2018, the Company does not believe that it is reasonably possible that its unrecognized tax benefits would significantly change in the following 12 months. In assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in the near term. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. On December 22, 2017, the 2017 Tax Cuts and Jobs Act (Tax Act) was enacted into law and the new legislation contains several key tax provisions that affected us, including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. The Company is required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring the Company's U.S. deferred tax assets and liabilities, as well as reassessing the net realizability of the Company's deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), which allowed the Company to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. As a result, the Company previously provided a provisional estimate of the effect of the Tax Act in the Company's financial statements. In the fourth quarter of 2018, we completed our analysis to determine the effect of the Tax Act and recorded no material adjustments as of December 31, 2018.

Related Party Transactions (Not

Related Party Transactions (Notes)	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Management and Strategic Collaboration Agreement Effective in June 2016, the Company and Equilibria Capital Management ("Equilibria"), a company incorporated in Bermuda and a significant stockholder of the Company, entered into the management and strategic collaboration agreement. Under the Equilibria collaboration agreement, Equilibria, amongst other services, was engaged to provide certain strategic, management and capital raising advice to the Company. The Equilibria collaboration agreement was effective for three years and renewable thereafter only upon the mutual written agreement of both parties. The Equilibria collaboration agreement provided that it would automatically terminate upon the closing of an IPO or a strategic sale. During the term of the Equilibria collaboration agreement, the Company, in exchange for the services received, paid Equilibria a quarterly fee of $0.1 million (the “Equilibria Management Fee”). The Equilibria Management Fee can be paid in cash or, at the mutual agreement of the parties, in shares of the Company at a valuation equal to the Company’s most recent financing round. In addition to the Equilibria Management Fee, the Company agreed to pay Equilibria any expenses reasonably incurred in performing the services agreed. For the years ended December 31, 2017, the Company had incurred and paid in cash $0.3 million , respectively, of Equilibria Management Fees. These amounts are included in general and administrative expense in the consolidated statements of operations. As of December 31, 2017, the Company had an outstanding payable to Equilibria of $0.1 million . The management and strategic collaboration agreement was terminated upon consummation of the Merger in December 2017. There were no Equilibria Management Fees incurred during the year ended December 2018 and there was no outstanding payable as of December 31, 2018. For the provision of the management and strategic collaboration services, the Company also agreed to pay Equilibria an incentive fee equal to 2% of the post-money market value of the Company on the date of its IPO. Such fee would be payable in shares with a per-share price equal to the price set for the sale of the Company’s shares to other investors in its IPO. The Company and Equilibria may have jointly agreed to settle the incentive fee earlier, if deemed appropriate for achieving a successful IPO, through either a cash payment, issuance of shares, or a combination of the two. In the event that the Company was sold as part of a strategic sale, the incentive fee would be equal to 2% of the gross value paid by the purchaser in cash. In February 2017, the Company and Equilibria entered into an amendment of the Equilibria collaboration agreement. Under the amendment, in the event that the Company entered into a reverse merger transaction in lieu of an initial public offering, the incentive fee to Equilibria was 2% of the post-merger fully diluted market value of the Company immediately after the closing of the reverse merger transaction, payable in a combination of cash and shares of common stock of the Company. The cash payment was based on the per share price equaling the intrinsic value of the Company’s shares in the Merger. The share-based component of the incentive fee was based on the post-closing fully diluted number of shares outstanding. In August 2017, the Company and Equilibria further amended the Equilibria collaboration agreement to fix the compensation payable to Equilibria in connection with the completion of the Merger, described above in Note 1. Accordingly, upon consummation of the Merger on December 29, 2017, the Company incurred $0.1 million in fees to Equilibria and issued 119,672 shares of common stock to Equilibria at a fair value of $0.9 million . These amounts are included in general and administrative expense in the consolidated statements of operations. Also, upon consummation of the Merger and pursuant to the amended Equilibria collaboration agreement, such agreement was terminated. Other Related Party Transactions The Company’s Chief Executive Officer, Dr. Angelos M. Stergiou (M.D., ScD h.c.) is a significant stockholder of the Company owning 1.9% and 7.8% of the Company’s outstanding share capital as of December 31, 2018 and 2017, respectively. Further transactions involving the Company and Dr. Stergiou are described in Note 6.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company evaluated all events or transactions that occurred after December 31, 2018 up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the consolidated financial statements, the Company did not have any material subsequent events. On March 6, 2019, the Company entered into a Warrant Exercise Agreement, or the Exercise Agreement, with one of the holders of our warrants issued in July 2018. Pursuant to the Exercise Agreement, such holder agreed that it would cash exercise up to 3,800,000 of its warrants issued in July 2018 into shares of common stock at a reduced exercise price of $1.10 per share for any warrants exercised prior to May 31, 2019. In addition to reducing the exercise price of the warrants, the Exercise Agreement also provides for the issuance of new warrants to purchase up to an aggregate of approximately 3,800,000 shares of common stock at an exercise price of $1.40 per share, or New Warrants, to be issued on a share-for-share basis in an amount equal to the number of the warrants that are cash exercised by the holder by May 31, 2019. To date, the holder has exercised approximately 1.2 million warrants for gross proceeds of $1.3 million and approximately 1.2 million New Warrants were issued. The Company may receive aggregate gross proceeds of up to approximately $4.2 million from the cash exercise if all of the warrants under the Exercise Agreement are exercised.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation.
Use of Estimates	Use of Estimates The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, beneficial conversion features associated with convertible notes, fair value of intangible assets acquired, carrying value of goodwill, fair value of contingent purchase price consideration, fair value of deferred tax liability assumed and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. The carrying amounts of the Company’s convertible notes that were outstanding as of December 31, 2017 approximate fair value due to the debt carrying a variable interest rate that is tied to the current London Interbank Offer Rate (“LIBOR”) rate. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level 3 of the fair value hierarchy. The fair value of the warrants is determined using a Black-Scholes pricing model.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers any highly liquid investments, such as money market funds, with an original maturity of three months or less to be cash and cash equivalents.
Restricted Cash and Cash Equivalents	Restricted Cash and Cash Equivalents Restricted cash consists of the minimum cash covenant as required by the debenture (see Note 9) and certificates of deposit on hand with the Company’s financial institutions as collateral for its corporate credit cards.
Intangible Assets	Intangible Assets Intangible assets are comprised of identifiable in-process research and development (“IPR&D”) assets and are considered indefinite-lived intangible assets and are assessed for impairment annually on October 1 or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss.
Goodwill	Goodwill Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit. The Company performs its annual goodwill impairment test at the reporting unit level on October 1 of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. Goodwill is evaluated for impairment using the simplified test of goodwill impairment as defined by FASB ASU No. 2017-04. Under the new guidance, goodwill impairment will be measured by the amount by which the carrying value of a reporting unit exceeds its fair value, without exceeding the carrying amount of goodwill allocated to that reporting unit. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit’s goodwill is less than the carrying value of the reporting unit’s goodwill.
Patents and Patent Application Costs	Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.
Legal Fees and Insurance Recoveries	Legal Fees and Insurance Recoveries There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal fees are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.
Share-based Compensation	Stock-based Compensation The Company follows the provisions of the FASB ASC Topic 718, “ Compensation— Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (“ASC 505-50”), “ Equity Based Payments to Non-Employees .” Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. Clinical study costs, a component of research and development expenses, are accrued over the service periods specified in the contracts and adjusted as necessary based on an ongoing review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as research and development expenses. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. Research and development expenses primarily consist of the intellectual property and research and development materials acquired, expenses from third parties who conduct research and development activities on behalf of the Company as well as related wages, benefits and other operating costs. The Company expenses in-process research and development projects acquired as asset acquisitions which have not reached technological feasibility and which have no alternative future use.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than not to be sustained. The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASBASC 740-10, “ Accounting for Income Taxes” (“ASC740-10”). These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. ASC740-10 requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company’s income tax provision or benefit. The recognition and measurement of benefits related to the company’s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company’s assumptions or changes in the Company’s assumptions in future periods are recorded in the period they become known.
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.
Comprehensive Loss	Comprehensive Loss The Company has no items of comprehensive income or loss other than net loss.
Preferred Stock	Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.
Convertible Instruments	Convertible Instruments The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument. The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Pending Adoption In August 2018, FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement . ASU 2018-13 modifies, adds and removes certain specific the disclosure requirements on fair value measurements in Topic 820 . The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Accounting , which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both non-employees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (i) liability-classified nonemployee awards that have not been settled as of the adoption date and (ii) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-07 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures. In February 2016, the FASB issued ASU No. 2016-02 , Leases . In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases , and No. 2018-11, Leases (Topic 842) - Targeted Improvements . The new standard establishes a right-of-use , or ROU , model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU No. 2016-02 is effective for interim and annual periods beginning after December 15, 2018, and the Company adopted the standard effective January 1, 2019. The standard requires the use of a modified retrospective transition approach, applying the new standard to all leases existing at the adoption date. The Company estimates that the adoption of the standard will result in the recognition of an ROU asset and lease liability of approximately $0.5 million . Recent Accounting Pronouncements Adopted In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash . ASU No. 2016-18 requires that restricted cash be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows. In accordance with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. The Company's consolidated statement of cash flows for the year ended December 31, 2017 was reclassified to to conform to the current year presentation. The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands): December 31, 2018 2017 Cash and cash equivalents $ 5,337 $ 2,319 Restricted cash and cash equivalents 114 10,431 Total cash, cash equivalents, restricted cash, and restricted cash equivalents $ 5,451 $ 12,750 In connection with the Company's Senior Secured Debenture described in Note 9, the Company was required to maintain a minimum of the lesser of $18.5 million or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December 31, 2017, the Company maintained $10.2 million of cash and cash equivalents in a restricted account. The Senior Secured Debenture was no longer outstanding as of December 31, 2018 . In addition, the Company maintained $0.1 million and $0.2 million as of December 31, 2018 and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards. In May 2017, the FASB issued ASU No. 2017-09, Scope of Modification Accounting . ASU No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's consolidated financial statements.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands): Year Ended December 31, 2018 2017 Common stock warrants 17,698 963 Stock options 395 10 Unvested restricted stock awards 13 13 18,106 986
Schedule of Cash and Cash Equivalents	The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands): December 31, 2018 2017 Cash and cash equivalents $ 5,337 $ 2,319 Restricted cash and cash equivalents 114 10,431 Total cash, cash equivalents, restricted cash, and restricted cash equivalents $ 5,451 $ 12,750

Acquisition (Tables)

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	The purchase price was calculated as follows (in thousands): Fair value of the Company's pre-Merger shares outstanding $ 12,487 Estimated fair value of the Company's pre-Merger stock options outstanding 32 Total purchase price $ 12,519 The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands): Assets acquired: Cash $ 1,812 Restricted cash 10,346 Prepaid expenses and other assets 3,103 Intangible assets 17,600 Goodwill 1,914 Total assets acquired $ 34,775 Liabilities assumed: Accounts payable and accrued expenses $ 5,692 Litigation settlement 1,300 Long-term debt 10,988 Contingent purchase price consideration of Apthera, Inc. 1,294 Warrant liability 1,309 Deferred tax liability 1,673 Total liabilities assumed $ 22,256 Net assets acquired $ 12,519
Summary of Pro Forma Information	The following summary pro forma consolidated financial information reflects the Merger with Galena as if it had occurred on January 1, 2017 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company’s results of operations would have been had the Merger in fact occurred on January 1, 2017, and is not intended to project the Company’s results of operations for any future period. Year Ended December 31, 2017 Net loss (in thousands) $ (24,089 ) Basic and diluted net loss per share $ 5.15

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consist of IPR&D acquired as part of the Merger. IPR&D assets represent research and development assets that have not yet reached commercialization. The Company's intangible assets consist of the following: Year Ended December 31, 2018 2017 NPS $ 5,700 $ 5,700 GALE-401 — 9,100 GALE-301 and GALE-302 2,800 2,800 $ 8,500 $ 17,600

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis	The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands): Description December 31, 2018 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Cash equivalents $ 5,195 $ 5,195 $ — $ — Total assets measured and recorded at fair value $ 5,195 $ 5,195 $ — $ — Liabilities: Warrants potentially settleable in cash $ 1,013 $ — $ — $ 1,013 Contingent consideration 4,326 — — 4,326 Total liabilities measured and recorded at fair value $ 5,339 $ — $ — $ 5,339 Description December 31, 2017 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Cash equivalents $ 1,662 $ 1,662 $ — $ — Restricted cash equivalents 10,245 10,245 — — Total assets measured and recorded at fair value $ 11,907 $ 11,907 $ — $ — Liabilities: Warrants potentially settleable in cash $ 1,309 $ — $ — $ 1,309 Contingent consideration 1,294 — — 1,294 Total liabilities measured and recorded at fair value $ 2,603 $ — $ — $ 2,603
Reconciliation of Level 3 Liabilities	A reconciliation of the change in the fair value of the contingent consideration liability for the years ended December 31, 2018 and 2017 is as follows (in thousands): Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Contingent consideration, January 1, 2017 $ — Contingent consideration acquired as part of the Merger 1,294 Contingent consideration, December 31, 2017 $ 1,294 Change in the estimated fair value of the contingent consideration 3,032 Contingent consideration, December 31, 2018 $ 4,326

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): December 31, 2018 December 31, 2017 Professional fees $ 540 $ 1,744 Compensation and related benefits 675 566 Clinical trial costs 858 51 Value-added tax — 426 Rebates and returns of former commercial products 138 223 Other 8 191 Accrued expenses and other current liabilities $ 2,219 $ 3,201

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Schedule of Debt	The Company has no debt outstanding at December 31, 2018. Debt outstanding consisted of the following at December 31, 2017: December 31, 2017 Debt Current portion of Senior Secured Debenture $ 8,377 Non-current portion of Senior Secured Debenture 2,611 Total debt $ 10,988

Legal Proceedings, Commitment_2

Legal Proceedings, Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The Company’s contractual obligations that may require future cash payments as of December 31, 2018 under the non-cancelable operating lease are as follows (in thousands): Amount 2019 $ 377 2020 224 Total $ 601

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Common Stock are Reserved for Future Issuance	Shares of common stock reserved for future issuance are as follows (in thousands): December 31, 2018 Warrants outstanding 17,698 Stock options outstanding 395 Options reserved for future issuance under the Company’s 2017 Equity Incentive Plan 421 Shares reserved for future issuance under the Employee Stock Purchase Plan 115 Restricted stock units 13 Total reserved for future issuance 18,642

Warrants to Acquire Shares of_2

Warrants to Acquire Shares of Common Stock (Tables)	12 Months Ended
	Dec. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Schedule Of Warrant Activity Table	The following is a summary of the Company's warrants to acquire shares of common stock activity for the year ended December 31, 2018 (in thousands): Warrant Issuance Outstanding, December 31, 2017 Granted Exercised Canceled/Expired Outstanding, December 31, 2018 Expiration July 2018 Offering — 15,268 — — 15,268 July 2023 Pre-funded July 2018 Offering — 4,675 (4,050 ) — 625 July 2023 Series A Convertible Preferred — 1,384 — 1,384 September 2023 2017 Equilibria 316 — — 316 December 2022 Galena February 2017 567 — — (534 ) 33 February 2022 Galena Other 80 — — (8 ) 72 January 2022 963 21,327 (4,050 ) (542 ) 17,698
Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model	The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: As of December 31, 2018 Warrant Issuance Outstanding (in thousands) Strike price (per share) Expected term (years) Volatility % Risk-free rate % Series A Convertible Preferred 1,384 $ 2.10 4.76 88.80 % 2.50 % Galena February 2017 33 $ 33.00 3.12 94.12 % 2.46 % Galena Other 72 $ 829.88 2.43 94.73 % 2.46 % As of December 31, 2017 Warrant Issuance Outstanding (in thousands) Strike price (per share) Expected term (years) Volatility % Risk-free rate % Galena February 2017 567 $ 33.00 4.12 79.29 % 2.09 % Galena Other 76 $ 888.22 2.74 72.46 % 2.00 %
Changes in Fair Value of Warrant Liability	The changes in fair value of the warrant liability for the year ended December 31, 2018 were as follows (in thousands): Warrant Issuance Warrant liability, December 31, 2017 Fair value of warrants granted Fair value of warrants canceled Adjustment to exercise price of warrants Change in fair value of warrants Warrant liability, December 31, 2018 Series A Convertible Preferred $ — $ 5,039 $ — $ 491 $ (4,520 ) $ 1,010 Galena February 2017 1,305 — (526 ) — (776 ) 3 Galena Other 4 — — — (4 ) — $ 1,309 $ 5,039 $ (526 ) $ 491 $ (5,300 ) $ 1,013

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Allocated Stock-based Compensation Expense	The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the years ended December 31, 2018 and 2017 , respectively (in thousands): Years Ended December 31, 2018 2017 Research and development $ 77 $ 729 General and administrative 318 2,440 Total stock-based compensation $ 395 $ 3,169
Assumptions for Option Grants Issued	The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the weighted average fair value of all its stock options granted during the year ended December 31, 2018: Risk free interest rate 2.73 % Volatility 80.83 % Expected lives (years) 6.20 Expected dividend yield — %
Stock Option Activity	The following table summarizes stock option activity of the Company for the year ended December 31, 2018: Total Number of Shares (In Thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (In Thousands) Outstanding at January 1, 2018 10 $ 1,240.55 1.00 $ — Granted 483 5.24 — Canceled (98 ) 5.30 $ — Outstanding at December 31, 2018 395 $ 37.09 9.01 $ — Options exercisable at December 31, 2018 53 $ 241.17 7.63 $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The loss before income taxes is as follows (in thousands): As of December 31, 2018 2017 U.S. $ (17,179 ) $ 265 Non - U.S. (11,869 ) (23,766 ) $ (29,048 ) $ (23,501 )
Schedule of Components of Income Tax Expense (Benefit)	The components of federal and state income tax expense are as follows (in thousands): As of December 31, 2018 2017 Current Federal $ (106 ) $ 76 State 45 138 Foreign — — Total current (61 ) 214 Deferred expense Federal (747 ) — State (570 ) 39 Foreign — — Total deferred (1,317 ) 39 Total income tax expense $ (1,378 ) $ 253
Schedule of Deferred Tax Assets and Liabilities	The components of net deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2018 2017 Net operating loss carryforwards $ 4,464 $ 1,028 Tax credit carryforwards 134 345 Stock-based compensation 2,223 2,550 Licensing deduction deferral 5,961 2,105 Other 56 395 Gross deferred tax assets 12,838 6,423 Valuation allowance (11,410 ) (4,658 ) Net deferred tax asset $ 1,428 $ 1,765 The components of net deferred tax liabilities are as follows (in thousands): As of December 31, 2018 2017 In-process research and development not subject to future amortization for tax purposes $ 1,785 $ 3,438 Gross deferred tax liability $ 1,785 $ 3,438 The net deferred tax liabilities are as follows (in thousands): As of December 31, 2018 2017 Net deferred tax asset $ 1,428 $ 1,765 Gross deferred tax liability 1,785 3,438 Net deferred tax liability $ 357 $ 1,673
Schedule of Effective Income Tax Rate Reconciliation	The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows: As of December 31, 2018 2017 U.S. federal statutory income tax rate (21.0 )% (34.0 )% State and local taxes, net of federal benefit (1.0 )% 0.4 % Foreign rate differential 8.6 % 34.4 % Permanent differences (1.5 )% 1.1 % Tax rate change and true-up (13.9 )% 0.3 % Other 0.1 % 0.2 % Valuation allowance 23.5 % 0.1 % Tax credits 0.5 % (1.4 )% Effective income tax rate (4.7 )% 1.1 %

Organization and Description _2

Organization and Description of Business (Narrative) (Details)	Dec. 29, 2017shares	Dec. 28, 2017$ / shares	Dec. 31, 2018$ / sharesshares	Dec. 31, 2017$ / sharesshares
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Common stock, par value (usd per share)			$ 0.0001	$ 0.0001
Common stock, shares outstanding (in shares) | shares	5,766,891		22,026,476	5,766,891
Galena Biopharma, Inc
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Reverse stock split ratio		0.0333
Common stock, par value (usd per share)		$ 0.0001
Private SELLAS Security Holders
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Common stock ownership percentage	67.50%
Private SELLAS Security Holders | Galena Biopharma, Inc
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Common stock conversion ratio	43.9972
Pre-Merger Securityholders
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Common stock ownership percentage	32.50%

Liquidity (Details)

Liquidity (Details) $ / shares in Units, $ in Thousands	Jul. 16, 2018USD ($)$ / sharesshares	May 01, 2018USD ($)	Mar. 09, 2018USD ($)$ / shares	Mar. 07, 2018USD ($)tranche$ / sharesshares	Dec. 29, 2017shares	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)shares
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Warrants issued (in shares) | shares	11,520,000				316,163
Sale of stock, price per share (in usd per share) | $ / shares	$ 2.10
Exercise price (usd per share) | $ / shares	$ 0.0001
Warrant term	5 years				5 years
Sale of stock, consideration received on transaction	$ 21,600
Preferred stock, shares issued (in shares) | shares							0	0
Cash and cash equivalents							$ 5,337	$ 2,319
Restricted cash and cash equivalents							114	$ 10,431
Accounts payable and accrued liabilities							$ 6,000
Series A- Convertible Preferred Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from issuance of private placement				$ 10,700
Series A- Convertible Preferred Stock | First Tranche
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from issuance of private placement			$ 6,000
Series A- Convertible Preferred Stock | Second Tranche
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from issuance of private placement		$ 4,700
Common Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sale of stock, number of shares issued in transaction | shares	6,845,000
Warrant term	5 years
Warrant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sale of stock, number of shares issued in transaction | shares	4,675,000
Sale of stock, price per share (in usd per share) | $ / shares	$ 2.0999
Warrant term	5 years
Purchase Agreement | Series A Non-voting Convertible
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Warrants issued (in shares) | shares				1,383,631
Warrant term				5 years 6 months
Preferred stock, shares issued (in shares) | shares				10,700
Conversion price (USD per share) | $ / shares							$ 1
Purchase Agreement | Series A- Convertible Preferred Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Conversion price (USD per share) | $ / shares			$ 5.80	$ 6.59
Number of tranches | tranche				2
Forecast
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from issuance of warrants						$ 4,200

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2019
Finite-Lived Intangible Assets [Line Items]
Impairment loss		$ 9,550	$ 0
Intangible assets	$ 8,500	8,500	17,600
Severance costs		0	1,883
Income tax expense (benefit)		(1,378)	253
GALE-401
Finite-Lived Intangible Assets [Line Items]
Intangible assets	0	0	9,100
Forecast | Accounting Standards Update 2016-02 | Subsequent Event
Finite-Lived Intangible Assets [Line Items]
Operating lease liability				$ 500
Right-of-use asset				$ 500
IPR&D | GALE-401
Finite-Lived Intangible Assets [Line Items]
Impairment loss	9,600
Intangible assets			$ 9,100
Upfront milestone payments, deposits and other assets	$ 500	$ 500

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies - Earnings per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	18,106	986
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	17,698	963
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	395	10
Unvested restricted stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	13	13

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies - Components of Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2018	May 18, 2018	Dec. 31, 2017	Dec. 31, 2016	May 10, 2016
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 5,337		$ 2,319
Restricted cash and cash equivalents	114		10,431
Total cash, cash equivalents, restricted cash, and restricted cash equivalents	5,451		12,750	$ 6,047
Corporate Credit Cards
Cash and Cash Equivalents [Line Items]
Restricted cash and cash equivalents	$ 100		200
Amendment Agreement | Secured Debt
Cash and Cash Equivalents [Line Items]
Maximum prepayment of principle if demanded					$ 18,500
Restricted cash		$ 8,500	$ 10,200

Acquisition - Summary of Purcha

Acquisition - Summary of Purchase Price (Details) $ in Thousands	Dec. 29, 2017USD ($)
Business Combinations [Abstract]
Fair value of the Company's pre-Merger shares outstanding	$ 12,487
Estimated fair value of the Company's pre-Merger stock options outstanding	32
Total purchase price	$ 12,519

Acquisition - Total Purchase Pr

Acquisition - Total Purchase Price Allocation (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 29, 2017
Assets acquired:
Intangible assets	$ 8,500	$ 17,600
Goodwill	$ 1,914	$ 1,914
Galena Biopharma, Inc
Assets acquired:
Cash			$ 1,812
Restricted cash			10,346
Prepaid expenses and other assets			3,103
Intangible assets			17,600
Goodwill			1,914
Total assets acquired			34,775
Liabilities assumed:
Accounts payable and accrued expenses			5,692
Litigation settlement			1,300
Long-term debt			10,988
Contingent purchase price consideration of Apthera, Inc.			1,294
Warrant liability			1,309
Deferred tax liability			1,673
Total liabilities assumed			22,256
Net assets acquired			$ 12,519

Acquisition - Pro Forma (Detail

Acquisition - Pro Forma (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2017
Business Combinations [Abstract]
Net loss (in thousands)		$ (24,089)
Basic net loss per share (usd per share)		$ 5.15
Diluted net loss per share (usd per share)	$ 5.15

Acquisition (Details)

Acquisition (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Business combination pro forma transaction costs		$ 8,700
Success fee and other transaction costs		$ 4,800
Stock issued for incentive fee payment in connection with acquisition during period shares		119,672
Stock issued for incentive fee payment in connection with acquisition during period		$ 941
Severance costs	$ 0	1,883
Production related impairments or charges		5,200
Galena Biopharma, Inc
Business Acquisition [Line Items]
Business combination pro forma transaction costs		$ 5,700

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 1,914	$ 1,914	$ 1,914
Impairment loss		9,550	0
Intangible assets	8,500	8,500	17,600
GALE-401
Finite-Lived Intangible Assets [Line Items]
Intangible assets	0	0	9,100
IPR&D | GALE-401
Finite-Lived Intangible Assets [Line Items]
Impairment loss	9,600
Intangible assets			$ 9,100
Upfront milestone payments, deposits and other assets	500	$ 500
Income tax expense (benefit)	$ (1,400)

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 8,500	$ 17,600
NPS
Finite-Lived Intangible Assets [Line Items]
Intangible assets	5,700	5,700
GALE-401
Finite-Lived Intangible Assets [Line Items]
Intangible assets	0	9,100
GALE-301 And GALE-302
Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 2,800	$ 2,800

Collaboration and License Agr_2

Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Thousands	Oct. 11, 2017	May 25, 2017	Feb. 24, 2017	Aug. 10, 2016	Oct. 30, 2015	Sep. 04, 2014	Sep. 11, 2006	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
License And Collaboration Agreements [Line Items]
Shares issued under license agreement		8,799				13,199
Research and development								$ 8,767	$ 6,067
Memorial Sloan Kettering Cancer Center
License And Collaboration Agreements [Line Items]
Upfront license fees								300
Minimum annual royalty payment						$ 100		100	100
Research funding costs								100	200	$ 200	$ 200
Milestone payments		$ 200				$ 17,400		500	700
License agreement expiration term						10 years
Milestone fee payments upon commencement of clinical trials		$ 300
License agreement outstanding amount payable								1,000	$ 1,000
License Agreement Terms | Memorial Sloan Kettering Cancer Center
License And Collaboration Agreements [Line Items]
Percentage of fully diluted share capital						1.50%
Upfront license fees						$ 1,300
Memorial Sloan Kettering Cancer Center Amended And Restated License Agreement
License And Collaboration Agreements [Line Items]
Shares issued under license agreement		15,399
Memorial Sloan Kettering Cancer Center Amended And Restated License Agreement | Memorial Sloan Kettering Cancer Center
License And Collaboration Agreements [Line Items]
Milestone fee payments upon commencement of clinical trials		$ 400
First MSK Amendment | Memorial Sloan Kettering Cancer Center
License And Collaboration Agreements [Line Items]
Shares issued under license agreement					10,867
Percentage of fully diluted share capital					1.00%
Second MSK Amendment | Memorial Sloan Kettering Cancer Center
License And Collaboration Agreements [Line Items]
Milestone payments	$ 700
Stock issued during period shares conversion of debt in connection with licensing agreement				13,815
Additional shares issued in connection with licensing agreement				30,314
Research and development				$ 2,000
License agreement outstanding amount payable				$ 900
Maximum number of days to make payments	60 days
Second Amended and Restated Exclusive License Agreement | Memorial Sloan Kettering Cancer Center
License And Collaboration Agreements [Line Items]
Shares issued under license agreement		74,795
Additional shares issued in connection with licensing agreement		7,700
Advaxis Collaboration Agreement
License And Collaboration Agreements [Line Items]
Royalty payment, maximum rate								$ 1,000,000
Advaxis Collaboration Agreement | Maximum
License And Collaboration Agreements [Line Items]
Non-refundable milestone payments			$ 108,000
Non-refundable sales milestone payments			$ 250,000
The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
License And Collaboration Agreements [Line Items]
Milestone payments							$ 3,800
Annual maintenance fee							$ 200
Chief Executive Officer Co-Founder | Memorial Sloan Kettering Cancer Center
License And Collaboration Agreements [Line Items]
Shares issued under license agreement						6,599
Co-founder | Memorial Sloan Kettering Cancer Center
License And Collaboration Agreements [Line Items]
Shares issued under license agreement						6,599

Fair Value Measurements - Conti

Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Liabilities:
Warrants potentially settleable in cash	$ 1,013	$ 1,309
Unobservable Inputs (Level 3)
Liabilities:
Contingent consideration	4,326	1,294	$ 0
Fair Value, Measurements, Recurring
Assets:
Cash equivalents	5,195	1,662
Restricted cash equivalents		10,245
Total assets measured and recorded at fair value	5,195	11,907
Liabilities:
Warrants potentially settleable in cash	1,013	1,309
Contingent consideration	4,326	1,294
Total liabilities measured and recorded at fair value	5,339	2,603
Fair Value, Measurements, Recurring | Quoted Prices In Active Markets (Level 1)
Assets:
Cash equivalents	5,195	1,662
Restricted cash equivalents		10,245
Total assets measured and recorded at fair value	5,195	11,907
Liabilities:
Warrants potentially settleable in cash	0	0
Contingent consideration	0	0
Total liabilities measured and recorded at fair value	0	0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Assets:
Cash equivalents	0	0
Restricted cash equivalents		0
Total assets measured and recorded at fair value	0	0
Liabilities:
Warrants potentially settleable in cash	0	0
Contingent consideration	0	0
Total liabilities measured and recorded at fair value	0	0
Fair Value, Measurements, Recurring | Unobservable Inputs (Level 3)
Assets:
Cash equivalents	0	0
Restricted cash equivalents		0
Total assets measured and recorded at fair value	0	0
Liabilities:
Warrants potentially settleable in cash	1,013	1,309
Contingent consideration	4,326	1,294
Total liabilities measured and recorded at fair value	$ 5,339	$ 2,603

Fair Value Measurements - Recon

Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2011
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Change in fair value of contingent consideration	$ (3,032)	$ 0
Unobservable Inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance Liabilities	1,294	0
Contingent consideration acquired as part of the Merger		1,294
Change in fair value of contingent consideration	3,032
Ending Balance Liabilities	$ 4,326	$ 1,294
Apthera, Inc.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration payable, maximum amount			$ 32,000

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Professional fees	$ 540	$ 1,744
Compensation and related benefits	675	566
Clinical trial costs	858	51
Value-added tax	0	426
Rebates and returns of former commercial products	138	223
Other	8	191
Accrued expenses and other current liabilities	$ 2,219	$ 3,201

Debt - Summary of Debt (Details

Debt - Summary of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Current portion of Senior Secured Debenture	$ 0	$ 8,377
Non-current portion of Senior Secured Debenture	$ 0	2,611
Total debt		10,988
Secured Debt | Securities Purchase Agreement
Debt Instrument [Line Items]
Current portion of Senior Secured Debenture		8,377
Non-current portion of Senior Secured Debenture		$ 2,611

Debt - Senior Secured Debenture

Debt - Senior Secured Debenture (Details) - USD ($)	Nov. 10, 2018	Nov. 05, 2018	May 10, 2016	Dec. 31, 2018	Dec. 31, 2017	Jul. 16, 2018	May 18, 2018	Dec. 29, 2017
Debt Instrument [Line Items]
Warrants issued (in shares)						11,520,000		316,163
Outstanding principal					$ 10,200,000
Principal redeemed				$ 2,800,000
Debt instrument, redemption, principal amount redeemed, shares				659,529
Debt amount redeemed, settled in cash				$ 600,000
Decrease in restricted cash				1,800,000
Gain on extinguishment of debt				766,000	0
Securities Purchase Agreement | Secured Debt
Debt Instrument [Line Items]
Fixed coupon rate	9.00%		6.375%
Principal amount of debt			$ 25,530,000
Warrants issued (in shares)			3,333
Proceeds from issuance of debt and warrants			$ 23,400,000
Amendment Agreement | Secured Debt
Debt Instrument [Line Items]
Final payment of interest	$ 800,000				800,000
Debt instrument, covenant, compensating cash balance			$ 18,500,000
Restricted cash					$ 10,200,000		$ 8,500,000
JGB Action
Debt Instrument [Line Items]
Restricted cash		$ 1,600,000
Balance of restricted cash over senior secured debenture		1,600,000
Loss contingency, damages awarded, value		6,600,000
Gain on reimbursement of legal fees		5,000,000
Gain on extinguishment of debt		$ 800,000		$ 800,000

Debt - Convertible Debt (Detail

Debt - Convertible Debt (Details) - USD ($)	1 Months Ended		12 Months Ended
	Nov. 30, 2018	Apr. 30, 2018	Dec. 31, 2018
Debt Instrument [Line Items]
Common stock acquired in exchange for warrants (in shares)			412,667
Convertible Notes Payable | Convertible Promissory Notes
Debt Instrument [Line Items]
Debt instrument, face amount			$ 1,000,000
Common stock acquired in exchange for warrants (in shares)			412,667
Debt instrument, interest rate, stated percentage			5.00%
Debt instrument, convertible, conversion price (in USD per share)			$ 7
Warrants and rights outstanding		$ 800,000
Conversion of units (in shares)		118,644
Principal and interest expense, debt	$ 200,000

Legal Proceedings, Commitment_3

Legal Proceedings, Commitments and Contingencies (Details) $ in Thousands	Nov. 05, 2018USD ($)	Oct. 23, 2018counterclaim	May 18, 2018USD ($)counterclaim	Jul. 24, 2017USD ($)	Oct. 31, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Loss Contingencies [Line Items]
Litigation settlement with issuance of common stock						$ 1,250	$ 0
Litigation settlement insurance recovery					$ 500
Gain on extinguishment of debt						766	0
Operating leases, rent expense						300	200
JGB (Cayman) Newton Ltd
Loss Contingencies [Line Items]
Loss contingency, number of counterclaims | counterclaim		4	7
Restricted cash	$ 1,600
Loss contingency, damages awarded, value	6,600
Legal fees						5,000
Gain on extinguishment of debt	$ 800					$ 800
Pending Litigation | Patel vs Galena biopharma, Inc
Loss Contingencies [Line Items]
Payments for legal settlement				$ 50
Litigation settlement with issuance of common stock				$ 1,250
Secured Debt | Amendment Agreement
Loss Contingencies [Line Items]
Restricted cash			$ 8,500				$ 10,200

Legal Proceedings, Commitment_4

Legal Proceedings, Commitments and Contingencies - Schedule of Future Minimum Rental Commitments for Operating Leases (Details) $ in Thousands	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 377
2020	224
Total	$ 601

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - USD ($)	Jul. 16, 2018	May 01, 2018	Mar. 09, 2018	Mar. 07, 2018	Dec. 29, 2017	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	May 31, 2018
Class of Stock [Line Items]
Preferred stock, shares authorized (in shares)							5,000,000	5,000,000
Preferred stock, par value (usd per share)							$ 0.0001	$ 0.0001
Preferred stock, shares issued (in shares)							0	0
Warrants issued (in shares)	11,520,000				316,163
Proceeds from issuance of preferred stock, preference stock, and warrants							$ 9,647,000	$ 0
Shares issued upon conversion (in shares)	3,748,184
Convertible preferred stock converted to other securities	$ 7,871,186
Exercise price (usd per share)	$ 2.10				$ 7.42				$ 6.59
Warrant term	5 years				5 years
Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision						$ 8,700,000	8,654,000	0
Increase (decrease) in fair value of warrant liability							$ 491,000	$ 0
Common stock, shares authorized (in shares)							350,000,000	350,000,000
Common stock, par value (usd per share)							$ 0.0001	$ 0.0001
Sale of stock, price per share (in usd per share)	$ 2.10
Common stock warrant, shares to purchase	1
Exercise price (usd per share)	$ 0.0001
Sale of stock, consideration received on transaction	$ 21,600,000
Purchase Agreement | Private Placement First Closing
Class of Stock [Line Items]
Warrants issued shares (in shares)			774,186
Series A Non-voting Convertible | Purchase Agreement
Class of Stock [Line Items]
Preferred stock, par value (usd per share)				$ 0.0001
Preferred stock, shares issued (in shares)				10,700
Warrants issued (in shares)				1,383,631
Proceeds from issuance of preferred stock, preference stock, and warrants				$ 10,700,000
Shares issued upon conversion (in shares)				1,844,835
Conversion price (USD per share)							$ 1
Warrant term				5 years 6 months
Series A- Convertible Preferred Stock | Private Placement First Closing
Class of Stock [Line Items]
Deemed dividend on beneficial conversion feature of convertible preferred stock		$ 2,500,000	$ 2,000,000
Series A- Convertible Preferred Stock | Purchase Agreement
Class of Stock [Line Items]
Conversion price (USD per share)			$ 5.80	$ 6.59
Series A- Convertible Preferred Stock | Purchase Agreement | Private Placement First Closing
Class of Stock [Line Items]
Proceeds from issuance of preferred stock, preference stock, and warrants			$ 6,000,000
Convertible preferred stock issued shares (in shares)			5,987
Series A- Convertible Preferred Stock | Purchase Agreement | Private Placement Second Closing
Class of Stock [Line Items]
Proceeds from issuance of preferred stock, preference stock, and warrants			$ 4,700,000
Convertible preferred stock issued shares (in shares)			4,713
Warrants issued shares (in shares)			609,445
Warrant
Class of Stock [Line Items]
Shares issued upon conversion (in shares)	3,748,184
Warrant term	5 years
Sale of stock, number of shares issued in transaction	4,675,000
Sale of stock, price per share (in usd per share)	$ 2.0999
Common Stock
Class of Stock [Line Items]
Warrant term	5 years
Sale of stock, number of shares issued in transaction	6,845,000

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details) - shares shares in Thousands	Dec. 31, 2018	Dec. 31, 2017
Equity [Abstract]
Warrants outstanding (in shares)	17,698	963
Stock options outstanding (in shares)	395	10
Options reserved for future issuance under the Company's 2017 Incentive Plan (in shares)	421
Shares reserved for future issuance under the Employee Stock Purchase Plan (in shares)	115
Restricted stock units (in shares)	13
Total reserved for future issuance (in shares)	18,642

Warrants to Acquire Shares of_3

Warrants to Acquire Shares of Common Stock - Schedule of Warrant Activity (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2018shares
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance (in shares)	963
Granted (in shares)	21,327
Exercised (in shares)	(4,050)
Canceled/Expired (in shares)	(542)
Warrants outstanding , Ending balance (in shares)	17,698
July 2018 Offering
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance (in shares)	0
Granted (in shares)	15,268
Exercised (in shares)	0
Canceled/Expired (in shares)	0
Warrants outstanding , Ending balance (in shares)	15,268
Pre-funded 2018 Offering
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance (in shares)	0
Granted (in shares)	4,675
Exercised (in shares)	(4,050)
Canceled/Expired (in shares)	0
Warrants outstanding , Ending balance (in shares)	625
Series A Convertible Preferred
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance (in shares)	0
Granted (in shares)	1,384
Exercised (in shares)	0
Warrants outstanding , Ending balance (in shares)	1,384
2017 Equilibria
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance (in shares)	316
Granted (in shares)	0
Exercised (in shares)	0
Warrants outstanding , Ending balance (in shares)	316
Galena February 2017
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance (in shares)	567
Granted (in shares)	0
Exercised (in shares)	0
Canceled/Expired (in shares)	(534)
Warrants outstanding , Ending balance (in shares)	33
Galena Other
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance (in shares)	80
Granted (in shares)	0
Exercised (in shares)	0
Canceled/Expired (in shares)	(8)
Warrants outstanding , Ending balance (in shares)	72

Warrants to Acquire Shares of_4

Warrants to Acquire Shares of Common Stock - Narrative (Details)	1 Months Ended	12 Months Ended
	Apr. 30, 2018USD ($)shares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)	Jul. 16, 2018$ / shares	May 31, 2018$ / shares	Dec. 29, 2017$ / shares
Class of Warrant or Right [Line Items]
Shares issued for cancellation of warrants (in shares)		54,613
Surrender and cancellation of warrants (in shares)		121,667
Common stock acquired in exchange for warrants (in shares)		412,667
Fair value of consideration exchanged | $		$ 1,200,000
Loss On Settlement Of Warrants Liability | $		$ 727,000	$ 0
Exercise price (usd per share) | $ / shares				$ 2.10	$ 6.59	$ 7.42
Galena February 2017
Class of Warrant or Right [Line Items]
Class of warrant or right canceled		534,334
Series A Convertible Preferred
Class of Warrant or Right [Line Items]
Exercise price (usd per share) | $ / shares		$ 6.59
Convertible Promissory Notes | Convertible Notes Payable
Class of Warrant or Right [Line Items]
Debt instrument, face amount | $		$ 1,000,000
Common stock acquired in exchange for warrants (in shares)		412,667
Warrants and rights outstanding | $	$ 800,000
Conversion of units (in shares)	118,644
Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input						0.9010
Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input		0				0.0220
Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input		0				0

Warrants to Acquire Shares of_5

Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	17,698	963
Series A Convertible Preferred
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	1,384	0
Strike price (in usd per share)	$ 2.10
Expected term (years)	4 years 9 months 4 days
Volatility %	88.80%
Risk-free rate %	2.50%
Galena February 2017
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	33	567
Strike price (in usd per share)	$ 33	$ 33
Expected term (years)	3 years 1 month 13 days	4 years 1 month 13 days
Volatility %	94.12%	79.29%
Risk-free rate %	2.46%	2.09%
Galena Other
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	72	80
Strike price (in usd per share)	$ 829.88
Expected term (years)	2 years 5 months 5 days
Volatility %	94.73%
Risk-free rate %	2.46%
Warrants Classified As Liabilities, Other
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)		76
Strike price (in usd per share)		$ 888.22
Expected term (years)		2 years 8 months 26 days
Volatility %		72.46%
Risk-free rate %		2.00%

Warrants to Acquire Shares of_6

Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, Beginning balance	$ 1,309
Fair value of warrants granted	5,039
Fair value of warrants canceled	(526)
Adjustment to exercise price of warrants	491
Change in fair value of warrants	(5,300)
Warrant liability, Ending balance	1,013
Series A Convertible Preferred
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, Beginning balance	0
Fair value of warrants granted	5,039
Fair value of warrants canceled	0
Adjustment to exercise price of warrants	491
Change in fair value of warrants	(4,520)
Warrant liability, Ending balance	1,010
Galena February 2017
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, Beginning balance	1,305
Fair value of warrants granted	0
Fair value of warrants canceled	(526)
Adjustment to exercise price of warrants	0
Change in fair value of warrants	(776)
Warrant liability, Ending balance	3
Galena Other
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, Beginning balance	4
Fair value of warrants granted	0
Fair value of warrants canceled	0
Adjustment to exercise price of warrants	0
Change in fair value of warrants	(4)
Warrant liability, Ending balance	$ 0

Warrants to Acquire Shares of_7

Warrants to Acquire Shares of Common Stock - Warrants Classified as Equity (Details)	Jul. 16, 2018$ / sharesshares	Dec. 29, 2017year$ / sharesshares	Dec. 31, 2018	May 31, 2018$ / shares
Class of Warrant or Right [Line Items]
Warrants issued (in shares) | shares	11,520,000	316,163
Exercise price (usd per share)	$ 2.10	$ 7.42		$ 6.59
Warrant term	5 years	5 years
Fair value of warrants granted, per share		$ 5.60
Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input		0.9010
Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input | year		5
Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input		0.0220	0
Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input		0	0

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Jan. 01, 2019	Dec. 29, 2017	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage increase in number of shares available for future issuance under stock based awards			1.00%
Options, grants in period, net of forfeitures (in shares)				0
Weighted average exercise price, granted (USD per share)			$ 3.73
Averages contractual term			10 years
Expected dividend yield			0.00%
Unrecognized compensation cost			$ 0.9
Operating expenses weighted average period			2 years 1 month 17 days
Closing price of the Company's common stock (in USD per share)			$ 1.23
Share based compensation arrangement by share based payment award percentage earning of participants				15.00%
Shares reserved for issuance			18,642,000
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options, vesting period			3 years
Equity instruments other than options, outstanding, number (in shares)			13,000	13,000
Equity instruments other than options, outstanding, weighted average grant date fair value (in USD per share)			$ 52.94	$ 52.94
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance			265,000
Additional shares reserved for issuance			150,000
Stock-based compensation arrangement by share-based payment award, equity instruments other than options, employee stock purchase plan issuance term			10 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average vesting term			6 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average vesting term			4 years
2017 Equity Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance (in shares)			381,000
Options expire from date of grant		10 years
Percentage increase in number of shares available for future issuance under stock based awards		4.00%
Options, grants in period, net of forfeitures (in shares)				0
2017 Equity Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance (in shares)		1,686,000
Incentive Plan 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options assumed in merger (in shares)		10,171
Subsequent Event | 2017 Equity Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized (in shares)	1,686,000

Stock-Based Compensation - Allo

Stock-Based Compensation - Allocated Stock-based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	$ 395	$ 3,169
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	77	729
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	$ 318	$ 2,440

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions for Option Grants Issued (Details)	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk free interest rate	2.73%
Volatility	80.83%
Expected lives (years)	6 years 2 months 12 days
Expected dividend yield	0.00%

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding, beginning balance (in shares)	10	395	395
Granted (in shares)		483
Canceled (in shares)		(98)
Options outstanding, ending balance (in shares)	10	395
Exercisable (in shares)			53
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average exercise price, beginning balance (usd per share)		$ 1,240.55
Weighted average exercise price, granted (usd per share)		5.24
Weighted average exercise price, canceled (use per share)		5.30
Weighted average exercise price, ending balance (usd per share)	$ 1,240.55	$ 37.09
Weighted average exercise price, exercisable (usd per share)			$ 241.17
Weighted average remaining contractual term, outstanding (in years)	1 year	9 years 4 days
Weighted average remaining contractual term, options exercisable (in years)		7 years 7 months 17 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]
Stock options activity, aggregate intrinsic value, beginning balance		$ 0
Stock options activity, aggregate intrinsic value, granted		0
Stock options activity, aggregate intrinsic value, canceled		0
Stock options activity, aggregate intrinsic value, ending balance	$ 0	$ 0
Stock options activity, aggregate intrinsic value, exercisable			$ 0

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Tax Credit Carryforward [Line Items]
Operating loss and tax credit carryforwards limitations on use minimum change in ownership percentage	50.00%
Maximum indefinite lived deferred tax liability as percentage of net operating loss	8000.00%
Valuation allowance, deferred tax asset, increase (decrease), amount	$ 1,400
Impact on tax provision from unrecognized tax benefits	55	$ 72
Domestic Tax Authority
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	19,700
State and Local Jurisdiction
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	3,700
Research Tax Credit Carryforward | Domestic Tax Authority
Tax Credit Carryforward [Line Items]
Tax credit carryforwards, research	$ 100

Income Taxes - Schedule of Loss

Income Taxes - Schedule of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
U.S.	$ (17,179)	$ 265
Non - U.S.	(11,869)	(23,766)
Total	$ (29,048)	$ (23,501)

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Current
Federal	$ (106)	$ 76
State	45	138
Foreign	0	0
Total current	(61)	214
Deferred expense
Federal	(747)	0
State	(570)	39
Foreign	0	0
Total deferred	(1,317)	39
Total income tax expense	$ (1,378)	$ 253

Income Taxes - Components of Ne

Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Components of Deferred Tax Assets [Abstract]
Net operating loss carryforwards	$ 4,464	$ 1,028
Tax credit carryforwards	134	345
Stock-based compensation	2,223	2,550
Licensing deduction deferral	5,961	2,105
Other	56	395
Gross deferred tax assets	12,838	6,423
Valuation allowance	(11,410)	(4,658)
Net deferred tax asset	$ 1,428	$ 1,765

Income Taxes - Components of _2

Income Taxes - Components of Net Deferred Tax Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
In-process research and development not subject to future amortization for tax purposes	$ 1,785	$ 3,438
Gross deferred tax liability	$ 1,785	$ 3,438

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Net deferred tax asset	$ 1,428	$ 1,765
Gross deferred tax liability	1,785	3,438
Net deferred tax liability	$ 357	$ 1,673

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision Computed by Applying Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
U.S. federal statutory income tax rate	(21.00%)	(34.00%)
State and local taxes, net of federal benefit	(1.00%)	0.40%
Foreign rate differential	8.60%	34.40%
Permanent differences	(1.50%)	1.10%
Tax rate change and true-up	(13.90%)	0.30%
Other	0.10%	0.20%
Valuation allowance	23.50%	0.10%
Tax credits	0.50%	(1.40%)
Effective income tax rate	(4.70%)	1.10%

Income Taxes - Schedule of Chan

Income Taxes - Schedule of Changes to Company's Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning of the Year - unrecognized tax benefits	$ 72	$ 0
Increase/(Decrease) - prior year tax positions	(17)
Increase/(Decrease) - prior year tax positions		44
Increase - current year tax positions	0	28
End of the Year - unrecognized tax benefits	$ 55	$ 72

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Millions	Dec. 29, 2017	Jun. 30, 2016	Dec. 31, 2018	Dec. 31, 2017	Feb. 28, 2017
Related Party Transaction [Line Items]
Collaboration agreement, term		3 years
Payment for management fee		$ 0.1
Management fee expense				$ 0.3
Accrued compensation incentive				$ 0.1
Incentive fee percentage equal to post money market value			2.00%		2.00%
Incentive fee percentage equal to gross value paid by purchaser in cash			2.00%
Stock issued for incentive fee payment in connection with acquisition during period share	119,672
General and administrative expense	$ 0.9
Equilibria Collaboration Agreement
Related Party Transaction [Line Items]
Management fee payable	$ 0.1
Dr. Angelos M. Stergiou | Msk License Agreement
Related Party Transaction [Line Items]
Percentage of ownership outstanding share capital			1.90%	7.80%

Subsequent Events - Narrative (

Subsequent Events - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 06, 2019	Mar. 31, 2019	May 31, 2019	Dec. 31, 2018	Jul. 16, 2018	May 31, 2018	Dec. 29, 2017
Subsequent Event [Line Items]
Exercise price (usd per share)					$ 2.10	$ 6.59	$ 7.42
Number of securities called by warrants (in shares)					11,520,000		316,163
Exercised (in shares)				4,050,000
Warrant Exercise Agreement | Subsequent Event
Subsequent Event [Line Items]
Warrants exercisable (in shares)	3,800,000
Exercise price (usd per share)	$ 1.10
Proceeds from issuance of warrants	$ 1.3
Exercised (in shares)	1,200,000
Class of warrant or right, new warrants issued (in shares)	1,200,000
Common Stock | Warrant Exercise Agreement | Subsequent Event
Subsequent Event [Line Items]
Exercise price (usd per share)	$ 1.40
Number of securities called by warrants (in shares)	3,800,000
Forecast
Subsequent Event [Line Items]
Proceeds from issuance of warrants		$ 4.2
Forecast | Warrant Exercise Agreement | Subsequent Event
Subsequent Event [Line Items]
Proceeds from issuance of warrants			$ 4.2